WO2001045548A2 - Surgical needle with weeping tip and method of use - Google Patents

Surgical needle with weeping tip and method of use Download PDF

Info

Publication number
WO2001045548A2
WO2001045548A2 PCT/US2000/034365 US0034365W WO0145548A2 WO 2001045548 A2 WO2001045548 A2 WO 2001045548A2 US 0034365 W US0034365 W US 0034365W WO 0145548 A2 WO0145548 A2 WO 0145548A2
Authority
WO
WIPO (PCT)
Prior art keywords
needle
distal portion
porous
medicament
catheter
Prior art date
Application number
PCT/US2000/034365
Other languages
French (fr)
Other versions
WO2001045548A3 (en
Inventor
Robert A. Vantassel
David R. Holmes, Jr.
Robert S. Schwartz
Original Assignee
Tricardia, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricardia, L.L.C. filed Critical Tricardia, L.L.C.
Priority to AU22757/01A priority Critical patent/AU783463B2/en
Priority to DE60033688T priority patent/DE60033688T2/en
Priority to JP2001546291A priority patent/JP2003517863A/en
Priority to CA002394860A priority patent/CA2394860A1/en
Priority to EP00986533A priority patent/EP1239776B1/en
Publication of WO2001045548A2 publication Critical patent/WO2001045548A2/en
Publication of WO2001045548A3 publication Critical patent/WO2001045548A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3286Needle tip design, e.g. for improved penetration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • A61M2025/0057Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M2025/0073Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/329Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
    • A61M5/3291Shafts with additional lateral openings

Definitions

  • the present invention generally relates to surgical instruments and to instruments used to inject medicaments into a body wall or tissue.
  • cationic liposomes or a biolistic device i.e., a vaccine "gun” which "shoots" polynucleotides coupled to beads into tissue
  • a biolistic device i.e., a vaccine "gun” which "shoots" polynucleotides coupled to beads into tissue
  • any invasive means of introducing nucleotides poses problems of tissue trauma (particularly in long-term therapies) and presents limited access to certain target tissues, such as organs.
  • Means for non-invasive delivery of pharmaceutical preparations of peptides have the advantage of minimizing tissue trauma.
  • bioavailability of peptides following transdermal or mucosal transmission is limited by the relatively high concentration of proteases in these tissues.
  • Feigner, et al. reported that they obtained expression of protein from "naked" polynucleotides (i.e., DNA or RNA not associated with liposomes or a viral expression vector) injected into skeletal muscle tissue (Feigner, et al., Science, 247:1465, 1990; see also, PCT application WO 90/11092).
  • Feigner, et al. surmised that muscle cells efficiently take up and express polynucleotides because of the unique structure of muscle tissue, which is comprised of multinucleated cells, sarcoplasmic reticulum and a transverse tubular system which extends deep into the muscle cell.
  • heterologous nucleic acid into cells of striated muscle is generally considered effective to cause expression of DNA or RNA injected into the cells.
  • Gene transfer by injection into subjects of live cells containing nucleic acids that will express therapeutic genes in vivo is also greatly desired, particularly for treatment sites located within a body cavity that can be reached in a relatively non- invasive manner by the use of a catheter.
  • gene transfer by injection of nucleic acid or cells containing therapeutic genes is complicated when the injection site is both remote (i.e., located within a body cavity) and in motion.
  • a particularly difficult target for such therapeutic techniques is a beating heart and associated arterial tissue.
  • the present invention overcomes many of the problems in the art by providing a surgical needle with a weeping tip for microinjection of medicaments into a body surface.
  • the invention surgical needle comprises a nonporous hollow needle shaft having a proximal erid adapted to mate with a surgical instrument, a porous distal portion in fluid-tight connection to the needle shaft, and a point that is open, closed or has a solid partial plug.
  • the porous distal portion of the invention needle is adapted to cause a liquid injectate to weep or ooze therefrom multidirectionally under injection pressure while the distal portion and point of the needle are inserted into a body surface.
  • the invention needle has features that create a substantially uniform rate of weeping of injectate along the length of the porous distal portion thereof.
  • the invention surgical needle with weeping tip can be adapted for attachment to such surgical instruments as a syringe, but is preferably adapted for attachment to the distal tip of a catheter
  • surgical assemblage(s) useful for injecting a liquid medicament into a remote location in a subject in need thereof.
  • the invention surgical assemblage comprises a needle with a sharp distal point with or without flow-through, and a catheter with a porous distal portion (such as a porous polymer) attached to the distal end of the needle, wherein the porous distal portion of the catheter is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while inserted into a body surface.
  • the remainder of the catheter is non- porous to assure that the medicament will be delivered only to tissue in contact with the porous portion of the catheter.
  • the invention surgical needle and/or surgical assemblage is ideally suited for injection into tissue of medicaments containing nucleic acid encoding a therapeutic agent (or cells containing such nucleic acid).
  • the invention needle (when attached to an appropriate catheter) or invention surgical assemblage can be used to inject medicament(s) into the wall of a beating heart or other internal organ, without substantial loss of the medicament at the surface of the body wall and without substantial damage to tissue at the injection site caused by injectate.
  • the invention injection method comprises inserting the distal portion of the invention needle into the tissue of the subject and causing a therapeutic amount of the medicament to ooze multidirectionally from the needle into the tissue without substantial leakage or loss of the medicament at the surface of the tissue.
  • the invention method using the invention needle (or surgical assemblage) with porous distal portion is designed for injection of minute amounts of fluid into tissue or a body wall, hence the use of the term "microinjection" herein.
  • methods for injecting a medicament into a subject in need thereof comprising inserting the distal portion of the invention needle into an interior body wall or tissue of the subject and applying sufficient pressure to a liquid medicament in fluid communication with the distal portion of the needle to expel the medicament such that the medicament weeps multidirectionally from the pores in the distal portion thereof into the interior body wall or tissue without substantial leakage or loss of the medicament at the surface of the body wall.
  • the invention methods are particularly useful for injecting medicament(s) into an interior body wall or tissue that is subject to motion, for example, the wall of a beating heart during electrophysiologic testing, transmyocardial revascularization, and the like.
  • the present invention provides a method for injecting a medicament into tissue in a subject in need thereof comprising: inserting the distal portion of an invention needle into the tissue of the subject and causing a therapeutic amount of the medicament to ooze multidirectionally from the needle into the tissue without substantial damage to the tissue of the subject caused by injectate.
  • FIGURE 1 is a schematic drawing showing an exploded view of the invention needle with weeping tip and a catheter to which it attaches.
  • FIGURE 2 is a schematic drawing showing the invention needle with the electrical connector for attachment to an electrocardiogram.
  • FIGURE 3 is a schematic drawing showing the invention surgical assemblage comprising a catheter and a needle, wherein the porous distal portion is located in the flexible catheter.
  • the present invention overcomes many of the problems in the art by providing a surgical needle with a weeping tip for microinjection of medicaments into a body surface.
  • the invention surgical needle comprises a nonporous hollow needle shaft having a proximal end adapted to mate with a surgical instrument, a porous distal portion in fluid-tight connection to the needle shaft, and a point that is open, closed, or has a solid partial plug.
  • the distal portion of the invention needle is adapted to cause a liquid injectate to weep or ooze therefrom multidirectionally under injection pressure while the distal portion and point of the needle are inserted into a body surface.
  • the length of the porous distal portion of the needle is determined by its intended use (e.g., whether intended for injecting medicament into a blood vessel or into a kidney, and the like).
  • the porous distal portion is generally about 1mm to about 20 mm in length and has pores with an average largest dimension in the range from about 1.0 micron to about 200 microns, for example, in the range from about 3 microns to about 100 microns, or from about 5 microns to about 75 microns.
  • the invention surgical needle with weeping tip can be adapted for attachment to such surgical instruments as a syringe, but is preferably adapted for attachment to the distal tip of a nonporous catheter.
  • the assemblage of the needle and catheter is preferably steerable.
  • the needle can be attached to the distal tip of a steerable catheter (i.e., comprising a steering mechanism at the handle for controlling deflection of the distal tip section of the catheter shaft), such as is known in the art for injection of medicaments into a remote body cavity or organ wall.
  • the needle can be attached to a catheter with a porous distal portion and then the combination can be introduced into a steerable guidance catheter, such as is used in such surgical techniques as angioplasty, transmyocardial revascularization (TMR), percutaneous transmyocardial revascularization (PTMR), and the like, to direct the needle and catheter to the appropriate site for injection of a medicament.
  • Guidance catheters suitable for use in the invention assemblages and methods are commercially available, for example from such vendors as Eclipse Surgical Technologies (Sunnyvale, CA) and CardioGenesis Corp. (Sunnyvale, CA).
  • the surgical needle is fabricated from a metal commonly used to make surgical needles, such as stainless steel, nitinol, tantalum, elgiloy, and the like, and provided with a distal portion having a multiplicity of pores, while the proximal portion of the needle (i.e., the nonporous hollow needle shaft) is fluid-tight to prevent leakage of fluid therefrom. Consequently, in use it is important to insert the complete porous distal portion of the needle into tissue before and during injection of a medicament.
  • a metal commonly used to make surgical needles such as stainless steel, nitinol, tantalum, elgiloy, and the like
  • the porous distal portion of the surgical needle is adapted to create decreasing hydraulic impedance on injectate moving therethrough towards the point to cause a substantially uniform rate of weeping of injectate from the porous distal portion along the length thereof.
  • the decrease in hydraulic impedance can be of any type, for example, linear, exponential, Gaussian, and the like, and with a gradient in either longitudinal direction.
  • the size and/or number of the pores in the porous distal portion can increase along its length from the proximal end towards the point. Adjustment of the porosity along the length of the porous distal portion may also be in conjunction with an increasing interior diameter along the length of the porous portion from the proximal end towards the point as needed to offset a falling off of injection pressure on fluid exiting towards the distal end of the device. Alternatively, if a different gradient of injectate is desired, the pore number and or size can be arranged in any direction suitable to accomplish such a gradient.
  • the sharp point of the invention needle can be open, closed, or fitted with a solid partial plug to prevent the injectate from exiting as a single jet. If the point of the needle is open, the rate of flow from the open point can also be controlled by adjustment of the hydraulic impedance along the length of the distal portion of the needle to prevent the rate of fluid flow at the tip from substantially exceeding the rate of fluid flow along the porous portion adjacent to the point of the needle.
  • the point of the needle can be open, but restricted by a solid partial plug so that the distal tip of the needle is designed to operate similarly to the tip of a garden nozzle wherein the solid partial plug cooperates with the open tip to restrict exit of fluid, thereby preventing exit of the fluid as a single jet.
  • the tip (and a distal portion of the needle shaft) can be loosely covered or loosely sheathed with a porous material, such as the porous sintered metal mesh described above to create the porous distal portion of the needle.
  • a porous material such as the porous sintered metal mesh described above to create the porous distal portion of the needle.
  • the sheath is attached (e.g., fused or welded) to the needle shaft to create the porous portion from which injectate will weep or ooze (i.e., from the pores in the porous sheath).
  • the proximal end of the invention needle shaft is provided with a connector, such as a flange, hub, or the like, as is known in the art, for removable attachment of the needle to a surgical instrument, such as a syringe or a catheter.
  • a surgical instrument such as a syringe or a catheter.
  • the surgical instrument serves as a reservoir for the fluid medicament. Therefore, the connector is such that there is fluid communication between the needle and the surgical instrument.
  • the invention needle is mounted on the distal tip of the surgical instrument, which is adapted to apply or transmit pressure to the medicament within the nonporous hollow shaft of the needle.
  • the distal portion of the needle can be fabricated from any of a number of different "open cell" porous materials (i.e., materials in which the pores are interconnecting).
  • the distal portion can be fabricated from a porous sintered metal, such as forms a non-woven matrix of metal fibers selected from such metals as stainless steel, tantalum, elgiloy, nitinol, and the like, and suitable combinations of any two or more thereof.
  • the metal fibers will have a diameter in the range from about 1.0 micron to about 25 microns .
  • a non-woven matrix of metal fibers having these desired properties that can be used in manufacture of the porous distal portion of the invention needle is available from the Bekaeart Corporation (Marietta, GA), and is sold under the trademark, BEKIPOR® filter medium.
  • the distal porous portion of the needle can also be fabricated from such porous materials as a porous polymer, such as a porous polyimide, polyethylene, polypropylene, polytetrafluroethylene, and the like.
  • a porous polymer such as a porous polyimide, polyethylene, polypropylene, polytetrafluroethylene, and the like.
  • porous polymers are disclosed, for example, in U.S. Patent No. 5,913,856, which is incorporated herein by reference in its entirety.
  • a porous ceramic can be used, such as is known in the art for use in ceramic filters and separation membranes, or a porous metal (also known as an expanded metal) or carbon, such as is known in the art for use in filters or bone grafts.
  • Mott Corporation (Farmington, CT) manufactures porous metals for use in various types of filters.
  • the distal portion of the invention needle can be fabricated by wrapping the filter medium, which is available commercially as a flat sheet, one or more times around an axis while creating a hollow central core.
  • the porous distal portion of the needle can then be fused in fluid-tight fashion (e.g. welded) to a non-porous hollow needle shaft using methods known in the art.
  • a porous filter medium or metal mesh having an appropriate porosity gradient can be employed in fabrication of the porous portion.
  • a porous distal portion for the invention needle can be created from a non-porous material (e.g., a metal) using a cutting laser and techniques known in the art to punch pores into the needle segment (i.e. by a process of laser etching).
  • a non-porous material e.g., a metal
  • the nonporous hollow shaft, porous portion, and point of the invention needle can be fabricated of metal in a single piece, for example, from a conventional hypotube.
  • a metal -cutting laser is used to create a segment of the needle that has appropriate porosity, for example, a porosity gradient within a portion of the needle as disclosed herein to equalize fluid impedance along the length of the porous portion of the needle.
  • the porosity of the distal portion is generally in the range from about 50% to about 85%, for example, at least about 70%.
  • the multidirectional flow of medicament from the needle is controlled by a number of factors, for example, the size, multiplicity and arrangement of the pores in the distal portion, the viscosity of the liquid medicament, the pressure applied to the medicament via the surgical instrument to which it is attached (i.e., the "injection pressure"), and the like.
  • the injection pressure the pressure applied to the medicament via the surgical instrument to which it is attached
  • Those of skill in the art will know how to select and combine these factors to assure that the medicament weeps multidirectionally from the pores in the distal portion of the needle into tissue into which it is inserted without substantial surface leakage or tissue damage attributable to the injectate.
  • the flow of a liquid medicament from the needle can be adjusted to be at a rate slow enough for the injectate to be absorbed into tissue in the injection site without substantial disruption of cellular and membrane structures as would be caused by bolus or rapid injection, especially from a needle having a single opening.
  • needle 2 has a nonporous hollow needle shaft, a porous distal portion 6 having inter-connecting pores and a closed sharp tip 8. Injectate 12 oozes from the pores in the distal portion under injection pressure. The sharp tip 8 of needle 2 is closed so that no injectate flows from the point of the needle.
  • the proximal end of needle 2 is fitted with flange 10 for removable attachment to a catheter.
  • the distal end of catheter 16, which has at least one open lumen 14 for passage of injectate into needle 2 attaches to the proximal end of needle 2.
  • a hub for mating with a syringe is substituted for the flange at the proximal end of the needle.
  • the invention needle further comprises one or more sensor connectors for electrical attachment to an electrocardiogram.
  • the electrocardiogram can be used to determine contact between the needle tip and the tissue, or if multiple electrodes are present, to determine the depth of penetration.
  • the exterior of the needle shaft (not visible in this Figure) is coated with an insulator 18 and the connector 19 is attached directly to the proximal end (uncoated) of the needle shaft.
  • Electrical lead 20 can be threaded down the lumen of a catheter for attachment to an electrocardiogram. Multiple leads can also be used in order to determine depth of the needle. In this configuration, the electrocardiogram is recorded from all leads. The larger signal is present from those ECG leads that are intramyocardial.
  • the connector can be attached to the interior of the tip of the needle with an insulated connecting wire running down the hollow interior of the needle and catheter for attachment to an electrocardiogram.
  • the needle itself acts as the electrode for the electrocardiogram and can be used for monopolar sensing of electrical currents or impedance within the heart, brain, nerves, proximal arteries, and the like.
  • a return electrode can be provided by placing an ECG pad in electrical connection with the electrocardiogram on the exterior of the patient, for example on the exterior of the chest wall. It is also contemplated within the scope of the invention that a second electrode or sensor connector can be attached to the needle, for example to the exterior of the needle, spaced apart from the first electrode by at least about 0.5 mm, so as to provide two electrodes for sensing electrical currents within a subject's bodily organs. It is also possible that an electrode permanently implanted in a subject, such as belongs to a pacemaker, can be used as the return lead for remote bipolar sensing.
  • an electrocardiogram sensor attached to the invention needle can be used to confirm contact of the needle tip or proper insertion of the needle into the body wall of interest (e.g., the wall of a beating heart) before injection of the medicament into a treatment site.
  • the depth of needle insertion into the tissue is determined by an array of electrodes.
  • the invention needle having attached electrocardiogram sensor can also be used to judge whether such a prospective injection site is electrically active or not (i.e., whether the tissue is dead, hibernating due to lack of oxygen, or alive), and the like.
  • the invention surgical assemblage comprises a needle with a sharp distal point, and a catheter with a porous distal portion attached to the distal end of the needle, wherein the porous distal portion is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while the porous distal portion of the catheter is inserted into a body surface.
  • the catheter in the invention surgical assemblage can be a steerable catheter having a steering mechanism at the handle for controlling deflection of the distal tip section of the catheter shaft, thereby, in effect, creating a "steerable needle.”
  • the invention surgical assemblage can further comprise a guidance catheter of the type known in the art for guiding instruments used in angioplasty, as is described more fully hereinabove.
  • the needle and catheter with porous distal portion is introduced into (i.e., threaded through) the guidance catheter so that the needle and catheter with porous distal portion can be directed to the site of injection (e.g., threaded through a desired section of tissue) using the steerable guidance catheter.
  • the porous distal portion of the catheter is made of a flexible porous polymer, such as a porous polyimide, polyethylene, polytetrafluoroethylene, or polypropylene, and the like.
  • the porous distal portion may further have features that create increasing hydraulic impedance on injectate moving therethrough towards the needle, thereby causing uniform flow of the injectate therefrom along the length of the porous distal portion as the injectate moves therethrough towards the needle to offset the falling off of injection pressure on fluid as it moves towards the point of the device.
  • the flexibility of the porous segment in the assemblage facilitates injection of medicaments along a non-linear path.
  • the size, and/or number of pores in the porous portion of the catheter in the invention surgical assemblage can be selected to create any desired gradient of injectate along the course of the injection path.
  • the size, and/or number of pores can decrease along the length of the porous portion moving towards the connection with the n edle to allow for a substantially uniform rate of injectate weepage along the length of the porous portion.
  • the porous distal portion can also have a decreasing interior diameter along its length moving from the proximal end towards the connection with the needle to accomplish the same goal.
  • Figure 3 herein illustrates the invention surgical assemblage 22.
  • Non-porous needle 24 with a closed tip is attached to the distal end of flexible catheter 26, which has a porous distal portion 28.
  • Injectate 30 weeps from the pores in the flexible distal portion 28 of catheter 26.
  • the invention method comprises inserting the porous distal portion of the invention needle into the tissue of the subject and applying sufficient injection pressure to a liquid medicament in fluid communication with the porous distal portion of the needle to cause the medicament to ooze multidirectionally from the pores in the needle into the tissue.
  • the invention surgical assembly wherein the porous portion is not contained in the needle, but is a porous distal portion of an otherwise nonporous catheter, can be used in the invention injection methods to similar effect. If the point and porous portion of the needle or surgical assembly are inserted into the tissue before the medicament is injected, the injection of medicament is performed without substantial leakage or loss of medicament at the surface of the tissue or interior body wall.
  • medicaments includes all types of liquid substances (e.g., including solutions and suspensions) that have a beneficial or therapeutic effect.
  • medicaments suitable for use in the invention methods include biologically active agents, such as small molecule drugs, proteinaceous substances, polynucleotides or nucleic acids (e.g. heterologous DNA, or RNA) and vectors, liposomes, and the like, containing such nucleic acids or polynucleotides, as well as liquid preparations or formulations thereof.
  • the invention methods and devices are designed for injection of minute amounts of fluid medicaments into tissue or a body wall, for example, an interior body wall.
  • tissue or a body wall for example, an interior body wall.
  • the therapeutic amount of the medicament to be administered according to the invention method will vary depending upon the therapeutic goal to be accomplished, the size and age of the subject, the pharmacokinetics of the injectate, and the like.
  • a therapeutic amount according to the present invention is typically in the range from about 0.5 cc to about 2.0 cc.
  • the injectate Under injection pressure exerted upon a fluid medicament within the invention needle or surgical assemblage, the injectate will weep or ooze multidirectionally from the porous distal portion into surrounding tissue into which it is inserted, but should be prevented from exiting from the proximal portions of the invention devices.
  • Flow of the injectate into the surrounding tissue is contemplated to be at a slow rate, for example, in the range from about 0.1 cc per second to about 2.0 cc per second to allow absorption of and dissipation the medicament into the tissue without substantial tissue damage caused by the injectate, (e.g., pooling of the medicament is thereby avoided). So long as the injectate contains no particles (e.g. cells) larger than the pores in the distal portion of the needle, overall flow of the medicament into tissue will be proportional to the amount of pressure applied on the injectate.
  • the porous portion of the invention device is adapted to cause a increasing gradient of impedance to fluid flow as the fluid moves distally through the porous portion (i.e., towards the point of the needle), the medicament will not weep at a uniform flow rate along the length of the porous portion.
  • the combination of the needle and the surgical instrument to which it is attached be selected so that the amount of the medicament that oozes from the pores of the needle can be controlled by the operator.
  • the amount of the medicament that oozes from the pores of the needle can be controlled by the operator.
  • pressure on the medicament in the chamber sufficient to deliver 2 cc of the medicament from the pores of the distal portion of the needle while the distal portion is inserted into tissue of the subject will substantially assure that the subject receives 2 cc of the medicament.
  • This feature of the invention devices and methods is particularly advantageous when it is important to closely monitor the amount of the medicament delivered to the subject, for example, to avoid waste of the medicament, to accurately judge the efficacy of the treatment, and the like.
  • the invention methods can be used to deliver to a subject in need of gene therapy an therapeutic amount of a medicament containing an isolated therapeutic nucleic acid sequence, or a vector, Hposome, or cell, and the like, containing such a nucleic acid sequence operatively associated with regulatory nucleic acid for expression of the encoded therapeutic protein.
  • the invention devices and methods can be used to promote gene therapy by injection of such medicaments even when the injection site is located internally and/or is in constant motion. Therefore, in another embodiment according to the present invention, there are provided methods for injecting a therapeutic amount of a medicament into an interior body wall or tissue of a subject in need thereof.
  • the invention method comprises inserting the distal portion of the invention needle into an interior body wall or tissue of the subject and applying sufficient pressure to a liquid medicament in fluid communication with the distal portion of the needle to expel a therapeutic amount of the medicament such that the medicament weeps multidirectionally from the pores in the distal portion thereof into the interior body wall or tissue without substantial leakage or loss of the medicament at the surface of the body wall.
  • the body wall can be located within a natural body cavity or a surgically created opening.
  • the invention method utilizing the needle with weeping tip is particularly useful for injection of medicaments into the wall of an interior organ that is subject to motion during the injection procedure, for example, the wall of a beating heart or adjacent arterial walls during electrophysiologic testing, transmyocardial revascularization, and the like.
  • Additional internal organs subject to movement into which injections can be made using the invention methods include the stomach, esophagus, gallbladder, liver, bowel, kidney, lung, and the like.
  • isolated polynucleotide or isolated nucleic acid or isolated nucleic acid sequence
  • isolated polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g. a cDNA) independent of other sequences.
  • Therapeutic nucleic acids contemplated fpr use in the practice of the present invention are intended to include those which encode products which are toxic to the cells in which they are expressed; those that encode products which impart a beneficial property to a subject; and those that transcribe nucleic acids which modulate transcription and/or translation of endogenous genes.
  • suitable therapeutic nucleic acids for administration into cardiac tissues using the invention devices and methods include those encoding growth factors that enhance apoptosis and cell growth, such as bFGF (basic fibroblast growth factor, also known as FGF-2), aFGF (also known as FGF-1), EGF (epithelial growth factor), VEGF (vascular epithelial growth factor), angiostatin, ecchystatin, IGFs (insulin-like growth factors), and the like.
  • growth factors that enhance apoptosis and cell growth such as bFGF (basic fibroblast growth factor, also known as FGF-2), aFGF (also known as FGF-1), EGF (epithelial growth factor), VEGF (vascular epithelial growth factor), angiostatin, ecchystatin, IGFs (insulin-like growth factors), and the like.
  • growth factors that enhance apoptosis and cell growth such as bFGF (basic fibroblast growth factor, also known as FGF-2),
  • Additional therapeutic nucleic acids useful in the practice of the present invention include genes that encode biologically active proteins of interest, such as, e.g., secretory proteins that can be released from said cell; enzymes that can metabolize a toxic substance to produce a non-toxic substance, or that metabolize an inactive substance to produce a useful substance; regulatory proteins; cell surface receptors; and the like.
  • biologically active proteins of interest such as, e.g., secretory proteins that can be released from said cell; enzymes that can metabolize a toxic substance to produce a non-toxic substance, or that metabolize an inactive substance to produce a useful substance
  • regulatory proteins e.g., cell surface receptors; and the like.
  • Useful genes include genes that encode blood clotting factors, such as human factors VIII and IX; genes that encode hormones, such as insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), alpha and beta seminal inhibins, and human growth hormone; genes that encode proteins, such as enzymes, the absence of which leads to the occurrence of an abnormal state; genes encoding cytokines or lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as alphai-antitrypsin; genes encoding substances that function as drugs, e.g., genes encoding the diphtheria and cholera toxins; and the like.
  • blood clotting factors such as human factors VIII and IX
  • genes that encode hormones such as insulin, parathyroid hormone, luteinizing hormone releasing
  • nucleic acid sequence information for proteins encoded by therapeutic nucleic acid(s) contemplated for use employed herein can be located in one of many public access databases, e.g., GENBANK, EMBL, Swiss-Prot, and PIR, or in related journal publications. Thus, those of skill in the art have access to sequence information for virtually all known genes. Those of skill in the art can obtain the corresponding nucleic acid molecule directly from a public depository or from the institution that published the sequence.
  • nucleic acid sequence encoding a desired protein has been ascertained, the skilled artisan can employ routine methods, e.g., polymerase chain reaction (PCR) amplification, to isolate the desired nucleic acid molecule from the appropriate nucleic acid library.
  • PCR polymerase chain reaction
  • Additional components that can optionally be incorporated into the invention constructs include selectable markers and genes encoding proteins required for retroviral packaging, e.g., thepo/ gene, the gag gene, the env gene, and the like.
  • Selectable markers contemplated for use in the practice of the present invention include antibiotic resistance genes, genes that enable cells to process metabolic
  • antibiotic resistance genes include genes which impart tetracycline resistance, genes that impart ampicillin resistance, neomycin resistance, hygromycin resistance, puromycin resistance, and the like.
  • the cells can be obtained from the subject or host (i.e., rather than a donor), modified as above, and then reintroduced into the subject using the invention devices and methods.
  • therapeutic nucleic acid can be introduced directly into cells obtained from a subject and the modified cells can be then injected into the subject.
  • the therapeutic nucleic acid may be stably incorporated into cells or may be transiently expressed using methods known in the art.
  • Modified cells are cultivated under growth conditions (as opposed to protein expression conditions) until a desired density is achieved.
  • Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene.
  • a selectable marker gene such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like
  • mammalian cells are transfected with a reporter gene (such as the E. coli ⁇ - galactosidase gene) to monitor transfection efficiency.
  • Selectable marker genes are typically not included in the transient transfections because the transfectants are typically not grown under selective conditions, and are usually analyzed within a few days after transfection.
  • gene replacement therapy involves the introduction of functionally active nucleic acids into the somatic cells of an affected subject to correct a gene defect or deficiency.
  • Genes that encode useful "gene therapy” proteins that are not normally transported outside the cell can be used in the invention if such genes are “functionally appended” to, or operatively associated with, a signal sequence that can "transport” the encoded product across the cell membrane.
  • a variety of such signal sequences are known and can be used by those skilled in the art without undue experimentation.
  • promoter refers to a specific nucleic acid sequence recognized by RNA polymerase, the enzyme that initiates RNA synthesis.
  • the promoter sequence is the site at which transcription can be specifically initiated under proper conditions.
  • Promoters contemplated for control of expression of exogenous nucleic acids employed in the practice of the present invention include inducible (e.g., minimal CMV promoter, minimal TK promoter, modified MMLV LTR), constitutive (e.g., chicken ⁇ - actin promoter, MMLV LTR (non-modified), DHFR), and/or tissue specific promoters.
  • inducible promoters contemplated for use in the practice of the present invention comprise transcription regulatory regions that function maximally to promote transcription of mRNA under inducing conditions. Examples of suitable inducible promoters include DNA sequences corresponding to: the E. coli lac operator responsive to IPTG (see Nakamura et al.
  • the metallothionein promoter metal-regulatory-elements responsive to heavy-metal (e.g., zinc) induction see Evans et al, U.S. Patent No. 4,870,009
  • the phage T71ac promoter responsive to IPTG see Studier et al, Meth. Enzymol, 185: 60-89, 1990; and U.S. Patent No. 4,952,496)
  • the heat-shock promoter the TK minimal promoter; the CMV minimal promoter; a synthetic promoter; and the like.
  • Exemplary constitutive promoters contemplated for use in the practice of the present invention include the CMV promoter, the SV40 promoter, the DHFR promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, elongation factor 1 a (EF 1 a) promoter, albumin promoter, APO Al promoter, cyclic AMP dependent kinase II (CaMKII) promoter, keratin promoter, CD3 promoter, immunoglobulin light or heavy chain promoters, neurofiliment promoter, neuron specific enolase promoter, L7 promoter, CD2 promoter, myosin light chain kinase promoter, HOX gene promoter, thymidine kinase (TK) promoter, RNA Pol II promoter, MYOD promoter, MYF5 promoter, phosphoglycerokinase (PGK) promoter, St
  • tissue specific refers to the substantially exclusive initiation of transcription in the tissue from which a particular promoter that drives expression of a given gene is derived (e.g., expressed only in T-cells, endothelial cells, smooth muscle cells, and the like).
  • tissue specific promoters contemplated for use in the practice of the present invention include the GH promoter, the NSE promoter, the GFAP promoter, neurotransmitter promoters (e.g., tyrosine hydroxylase, TH, choline acetyltransferase, ChAT, and the like), promoters for neurotropic factors (e.g., a nerve growth factor promoter, NT-3, BDNF promoters, and the like), and so on.
  • neurotransmitter promoters e.g., tyrosine hydroxylase, TH, choline acetyltransferase, ChAT, and the like
  • promoters for neurotropic factors e.g., a nerve growth factor promoter, NT-3, BDNF promoters, and the like
  • operatively associated with refers to the functional relationship of DNA with regulatory and effector sequences of nucleic acids, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences.
  • operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.
  • Gene transfer vectors contemplated for use herein are recombinant nucleic acid molecules that are used to transport nucleic acid into host cells for expression and/or replication thereof.
  • Expression vectors may be either circular or linear, and are capable of incorporating a variety of nucleic acid constructs therein.
  • Expression vectors typically come in the form of a plasmid that, upon introduction into an appropriate host cell, results in expression of the inserted nucleic acid.
  • Suitable expression vectors for use herein are well known to those of skill in the art and include recombinant DNA or RNA construct(s), such as plasmids, phage, recombinant virus or other vectors that, upon introduction into an appropriate host cell, result(s) in expression of the inserted DNA.
  • Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. Expression vectors typically further contain other functionally important nucleic acid sequences encoding antibiotic resistance proteins, and the like.
  • the amount of therapeutic nucleic acid introduced into a subject can be varied by those of skill in the art.
  • the amount of nucleic acid introduced can be varied by varying the amount of plaque forming units (PFU) of the viral vector.
  • Exemplary eukaryotic expression vectors include eukaryotic constructs, such as the pSV-2 gpt system (Mulligan et al, Nature 212:108-114, 1979); pBlueSkript (Stratagene, La Jolla, CA), the expression cloning vector described by Genetics Institute (Science 228:810-815. 1985), and the like. Each of these plasmid vectors is capable of promoting expression of the protein product of the nucleic acid of interest.
  • Suitable means for introducing (transducing) expression vectors containing therapeutic nucleic acid constructs into cells of a subject treated according to the invention methods include infection employing viral vectors (see, e.g., U.S. Patent
  • the transduced nucleic acid can optionally include sequences which allow for its extrachromosomal (i.e., episomal) maintenance, or the transduced nucleic acid can be donor nucleic acid that integrates into the genome of the host.
  • a gene transfer vector contemplated for use herein is a viral vector, such as Adenovirus, adeno-associated virus, a herpes-simplex virus based vector, a synthetic vector for gene therapy, and the like (see, e.g., Suhr et al. Arch. of Neurol. 5_0_: 1252-1268, 1993).
  • a gene transfer vector employed herein is a retroviral vector.
  • Retroviral vectors contemplated for use herein are gene transfer plasmids that have an expression construct containing an exogenous nucleic acid residing between two retroviral LTRs.
  • Retroviral vectors typically contain appropriate packaging signals that enable the retroviral vector, or RNA transcribed using the retroviral vector as a template, to be packaged into a viral virion in an appropriate packaging cell line (see, e.g., U.S. Patent 4,650,764).
  • Suitable retroviral vectors for use herein are described, for example, in U.S. Patents 5,399,346 and 5,252,479; and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, each of which is hereby incorporated herein by reference, in its entirety. These documents provide a description of methods for efficiently introducing nucleic acids into human cells using such retroviral vectors.
  • retroviral vectors include, for example, mouse mammary tumor virus vectors (e.g., Shackleford et alPNAS, USA, 85:9655-9659, 1988), human immunodeficiency virus (e.g., Naldini et al. Science 222:165-320, 1996), and the like.
  • mouse mammary tumor virus vectors e.g., Shackleford et alPNAS, USA, 85:9655-9659, 1988
  • human immunodeficiency virus e.g., Naldini et al. Science 222:165-320, 1996), and the like.
  • helper cells which produce retroviral vector particles that are essentially free of replicating virus. See, for example, U.S. Patent 4,650,764; Miller, Human Gene Therapy, 1:5-14, 1990; Markowitz, et al, Journal of Virology, 6_K4):1120-1124, 1988; Watanabe, et al, Molecular and Cellular Biology, 3_02):2241-2249, 1983; Danos, et al, PNAS, Var:6460- 6464, 1988; and Bosselman, et al. , Molecular and Cellular Biology, 5): 1797-1806, 1987, which disclose procedures for producing viral vectors and helper cells that minimize the chances for producing a viral vector that includes a replicating virus.
  • Retroviral virions suitable for carrying out the invention methods are produced employing well-known methods for producing retroviral virions. See, for example, U.S. Patent 4,650,764; /7/er, supra 1990; Markowitz, et al, supra 1988;
  • nucleic acid encoding invention chimeric protein By introducing all of the necessary regulatory machinery, plus exogenous nucleic acid, selectable markers, and nucleic acid encoding invention chimeric protein, e.g., into a MARV retrovirus, highly efficient insertion of exogenous nucleic acids into targeted cells can be achieved.
  • the above-described viral constructs address several important problems confronted in the use of retroviruses in application of therapeutic gene transfer strategies to a variety of human diseases.
  • the retroviral vectors of the invention are capable of prolonged gene expression under conditions where conventionally integrated retroviruses are no longer transcriptionally active.
  • exogenous to said mammalian host or simply “exogenous” refers to nucleic acids not naturally found at levels sufficient to provide a function in the particular cell where transcription is desired.
  • exogenous nucleic acids can be either natural or synthetic nucleic acids, which are introduced into the subject in the form of DNA or RNA.
  • the nucleic acids of interest can be introduced directly or indirectly into a subject, for example, by the transfer of transformed cells into a subject using invention methods.
  • the subject mammals include: humans; domesticated animals, e.g., rat, mouse, rabbit, canine, feline, and the like; farm animals, e.g., chicken, bovine, ovine, porcine, and the like; animals of zoological interest, e.g., monkey, baboon, and the like

Abstract

The invention provides surgical needles with a porous distal portion from which a liquid injectate will weep or ooze multidirectionally under injection pressure while the porous distal portion of the needle is inserted into a body surface. The porous distal portion of the needle can be fabricated from a porous carbon, metal, ceramic or polymer and preferably has a decreasing gradient of impedance to fluid flowing to the point of the needle to compensate for the falling off of injection pressure as fluid moves towards the point, thereby ensuring uniform weeping of the injectate along the injection course. The needle is adapted for attachment to a catheter or syringe. In another embodiment, a surgical assemblage is provided wherein a porous distal portion having similar fluid flow characteristics is located along the distal end of a catheter, and a needle point is attached to the distal end of the catheter (e.g., a steerable catheter) for piercing tissue. A guidance catheter can be used to direct the invention devices to a remote internal injection site. The invention devices and methods can be used to inject fluids (including those containing nucleic acids for gene therapy) into interior body walls or tissue, such as a heating heart, without substantial loss of fluid and without substantial damage to tissue caused by injectate.

Description

HYPODERMIC NEEDLE WITH WEEPING TIP AND METHOD OF USE
FIELD OF THE INVENTION
The present invention generally relates to surgical instruments and to instruments used to inject medicaments into a body wall or tissue.
BACKGROUND OF THE INVENTION
The direct introduction of a drug, compound, biologically active peptide or protein into the cells of a patient can have significant therapeutic value. However, this approach also has several drawbacks. Of primary concern is the risk of potential toxicity, particularly at dosages sufficient to produce a biological response to the peptide. From a practical perspective, there is also the problem of the cost associated with isolating and purifying or synthesizing the peptides. Moreover, the clinical impact of the peptides is also limited by their relatively short half-life in vivo, which usually results from their degradation by any proteases present in the target tissue.
For these reasons, introduction of bioactive agents, including proteins, into a patient by delivery of a gene or a cell containing a gene that will express a therapeutic protein in the patient/host is an intriguing alternative to administering the substance. However, to date the principal means for introduction of foreign genetic material into a host has involved the integration of the gene into the host genome by, for example, transforming the host's cells with a viral vector. Direct in vivo gene transfer into postnatal animals has also been reported using DNA encapsulated in liposomes including DNA entrapped in proteoliposomes containing viral envelope receptor proteins. With respect to delivery systems for genes, means such as viral vectors which introduce the gene into the host's genome can present potential health risks associated with damage to the genetic material in the host cell. Use of cationic liposomes or a biolistic device (i.e., a vaccine "gun" which "shoots" polynucleotides coupled to beads into tissue) to deliver genes in vivo is preparation intensive and, in some cases, requires some experimentation to select proper particle sizes for transmission into target cells. Further, any invasive means of introducing nucleotides (e.g., injection) poses problems of tissue trauma (particularly in long-term therapies) and presents limited access to certain target tissues, such as organs.
Means for non-invasive delivery of pharmaceutical preparations of peptides, such as iontophoresis and other means for transdermal transmission, have the advantage of minimizing tissue trauma. However, it is believed that the bioavailability of peptides following transdermal or mucosal transmission is limited by the relatively high concentration of proteases in these tissues.
Injection of "naked DNA" directly into muscle has also been investigated at length. In 1984, work at the NIH was reported which showed that intrahepatic injection of naked, cloned plasmid DNA for squirrel hepatitis into squirrels produced both viral infection and the formation of antiviral antibodies in the squirrels (Seeger, et al, Proc.Nat'l.Acad.Sci USA, 81 :5849-5852, 1984). Several years later, Feigner, et al., reported that they obtained expression of protein from "naked" polynucleotides (i.e., DNA or RNA not associated with liposomes or a viral expression vector) injected into skeletal muscle tissue (Feigner, et al., Science, 247:1465, 1990; see also, PCT application WO 90/11092). Feigner, et al. surmised that muscle cells efficiently take up and express polynucleotides because of the unique structure of muscle tissue, which is comprised of multinucleated cells, sarcoplasmic reticulum and a transverse tubular system which extends deep into the muscle cell.
Today, injection of heterologous nucleic acid into cells of striated muscle is generally considered effective to cause expression of DNA or RNA injected into the cells. Gene transfer by injection into subjects of live cells containing nucleic acids that will express therapeutic genes in vivo is also greatly desired, particularly for treatment sites located within a body cavity that can be reached in a relatively non- invasive manner by the use of a catheter. However, gene transfer by injection of nucleic acid or cells containing therapeutic genes is complicated when the injection site is both remote (i.e., located within a body cavity) and in motion. A particularly difficult target for such therapeutic techniques is a beating heart and associated arterial tissue.
Further, even though the amount of the particular isolated therapeutic genes or cells injected into a patient is small, the costs involved in preparation of such therapeutic substances is high. Therefore, any injectate lost during transfer to the patient, for example, by leakage due to too rapid a transfer, represents a considerable monetary loss.
Accordingly, there is still a need in the art for new and better needles and injection systems or surgical assemblages suitable for microinjection of controlled amounts of therapeutic substances without substantial loss of injectate and without substantial damage to tissue, even upon repeat injections. There is a particular need for needles that are adapted for attachment to various types of catheters for such controlled delivery of therapeutic substances at remote locations within the body.
BRIEF DESCRIPTION OF THE INVENTION
The present invention overcomes many of the problems in the art by providing a surgical needle with a weeping tip for microinjection of medicaments into a body surface. The invention surgical needle comprises a nonporous hollow needle shaft having a proximal erid adapted to mate with a surgical instrument, a porous distal portion in fluid-tight connection to the needle shaft, and a point that is open, closed or has a solid partial plug. The porous distal portion of the invention needle is adapted to cause a liquid injectate to weep or ooze therefrom multidirectionally under injection pressure while the distal portion and point of the needle are inserted into a body surface. Preferably, the invention needle has features that create a substantially uniform rate of weeping of injectate along the length of the porous distal portion thereof.
The invention surgical needle with weeping tip can be adapted for attachment to such surgical instruments as a syringe, but is preferably adapted for attachment to the distal tip of a catheter
In another embodiment according to the present invention, there are provided surgical assemblage(s) useful for injecting a liquid medicament into a remote location in a subject in need thereof. The invention surgical assemblage comprises a needle with a sharp distal point with or without flow-through, and a catheter with a porous distal portion (such as a porous polymer) attached to the distal end of the needle, wherein the porous distal portion of the catheter is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while inserted into a body surface. The remainder of the catheter is non- porous to assure that the medicament will be delivered only to tissue in contact with the porous portion of the catheter.
The invention surgical needle and/or surgical assemblage is ideally suited for injection into tissue of medicaments containing nucleic acid encoding a therapeutic agent (or cells containing such nucleic acid). For example, the invention needle (when attached to an appropriate catheter) or invention surgical assemblage can be used to inject medicament(s) into the wall of a beating heart or other internal organ, without substantial loss of the medicament at the surface of the body wall and without substantial damage to tissue at the injection site caused by injectate.
Accordingly, in another embodiment according to the present invention, there are provided methods for injecting a medicament into tissue in a subject in need thereof. The invention injection method comprises inserting the distal portion of the invention needle into the tissue of the subject and causing a therapeutic amount of the medicament to ooze multidirectionally from the needle into the tissue without substantial leakage or loss of the medicament at the surface of the tissue. The invention method using the invention needle (or surgical assemblage) with porous distal portion is designed for injection of minute amounts of fluid into tissue or a body wall, hence the use of the term "microinjection" herein.
In another embodiment according to the present invention, there are provided methods for injecting a medicament into a subject in need thereof comprising inserting the distal portion of the invention needle into an interior body wall or tissue of the subject and applying sufficient pressure to a liquid medicament in fluid communication with the distal portion of the needle to expel the medicament such that the medicament weeps multidirectionally from the pores in the distal portion thereof into the interior body wall or tissue without substantial leakage or loss of the medicament at the surface of the body wall. The invention methods are particularly useful for injecting medicament(s) into an interior body wall or tissue that is subject to motion, for example, the wall of a beating heart during electrophysiologic testing, transmyocardial revascularization, and the like.
In yet another embodiment, the present invention provides a method for injecting a medicament into tissue in a subject in need thereof comprising: inserting the distal portion of an invention needle into the tissue of the subject and causing a therapeutic amount of the medicament to ooze multidirectionally from the needle into the tissue without substantial damage to the tissue of the subject caused by injectate.
It is a particular object of the present invention to provide devices and methods useful for simultaneously injecting a medicament from multiple orifices along an injection course, rather than delivering a bolus injection, as is the case with traditional hypodermic needles.
BRIEF DESCRIPTION OF THE FIGURE
FIGURE 1 is a schematic drawing showing an exploded view of the invention needle with weeping tip and a catheter to which it attaches. FIGURE 2 is a schematic drawing showing the invention needle with the electrical connector for attachment to an electrocardiogram.
FIGURE 3 is a schematic drawing showing the invention surgical assemblage comprising a catheter and a needle, wherein the porous distal portion is located in the flexible catheter.
DETAILED DESCRIPTION OF THE INVENTION
The present invention overcomes many of the problems in the art by providing a surgical needle with a weeping tip for microinjection of medicaments into a body surface. The invention surgical needle comprises a nonporous hollow needle shaft having a proximal end adapted to mate with a surgical instrument, a porous distal portion in fluid-tight connection to the needle shaft, and a point that is open, closed, or has a solid partial plug. The distal portion of the invention needle is adapted to cause a liquid injectate to weep or ooze therefrom multidirectionally under injection pressure while the distal portion and point of the needle are inserted into a body surface. Typically, the length of the porous distal portion of the needle is determined by its intended use (e.g., whether intended for injecting medicament into a blood vessel or into a kidney, and the like). However, the porous distal portion is generally about 1mm to about 20 mm in length and has pores with an average largest dimension in the range from about 1.0 micron to about 200 microns, for example, in the range from about 3 microns to about 100 microns, or from about 5 microns to about 75 microns.
The invention surgical needle with weeping tip can be adapted for attachment to such surgical instruments as a syringe, but is preferably adapted for attachment to the distal tip of a nonporous catheter. The assemblage of the needle and catheter is preferably steerable. For example, the needle can be attached to the distal tip of a steerable catheter (i.e., comprising a steering mechanism at the handle for controlling deflection of the distal tip section of the catheter shaft), such as is known in the art for injection of medicaments into a remote body cavity or organ wall. Alternatively, the needle can be attached to a catheter with a porous distal portion and then the combination can be introduced into a steerable guidance catheter, such as is used in such surgical techniques as angioplasty, transmyocardial revascularization (TMR), percutaneous transmyocardial revascularization (PTMR), and the like, to direct the needle and catheter to the appropriate site for injection of a medicament. Guidance catheters suitable for use in the invention assemblages and methods are commercially available, for example from such vendors as Eclipse Surgical Technologies (Sunnyvale, CA) and CardioGenesis Corp. (Sunnyvale, CA).
In one embodiment according to the present invention, the surgical needle is fabricated from a metal commonly used to make surgical needles, such as stainless steel, nitinol, tantalum, elgiloy, and the like, and provided with a distal portion having a multiplicity of pores, while the proximal portion of the needle (i.e., the nonporous hollow needle shaft) is fluid-tight to prevent leakage of fluid therefrom. Consequently, in use it is important to insert the complete porous distal portion of the needle into tissue before and during injection of a medicament.
In another embodiment according to the present invention, the porous distal portion of the surgical needle is adapted to create decreasing hydraulic impedance on injectate moving therethrough towards the point to cause a substantially uniform rate of weeping of injectate from the porous distal portion along the length thereof. The decrease in hydraulic impedance can be of any type, for example, linear, exponential, Gaussian, and the like, and with a gradient in either longitudinal direction.
For example, to create decreasing hydraulic impedance along the length of the porous portion, the size and/or number of the pores in the porous distal portion can increase along its length from the proximal end towards the point. Adjustment of the porosity along the length of the porous distal portion may also be in conjunction with an increasing interior diameter along the length of the porous portion from the proximal end towards the point as needed to offset a falling off of injection pressure on fluid exiting towards the distal end of the device. Alternatively, if a different gradient of injectate is desired, the pore number and or size can be arranged in any direction suitable to accomplish such a gradient.
The sharp point of the invention needle can be open, closed, or fitted with a solid partial plug to prevent the injectate from exiting as a single jet. If the point of the needle is open, the rate of flow from the open point can also be controlled by adjustment of the hydraulic impedance along the length of the distal portion of the needle to prevent the rate of fluid flow at the tip from substantially exceeding the rate of fluid flow along the porous portion adjacent to the point of the needle.
Alternatively, the point of the needle can be open, but restricted by a solid partial plug so that the distal tip of the needle is designed to operate similarly to the tip of a garden nozzle wherein the solid partial plug cooperates with the open tip to restrict exit of fluid, thereby preventing exit of the fluid as a single jet.
In another embodiment wherein the needle has an open tip, the tip (and a distal portion of the needle shaft) can be loosely covered or loosely sheathed with a porous material, such as the porous sintered metal mesh described above to create the porous distal portion of the needle. In this embodiment, the sheath is attached (e.g., fused or welded) to the needle shaft to create the porous portion from which injectate will weep or ooze (i.e., from the pores in the porous sheath).
The proximal end of the invention needle shaft is provided with a connector, such as a flange, hub, or the like, as is known in the art, for removable attachment of the needle to a surgical instrument, such as a syringe or a catheter. The surgical instrument serves as a reservoir for the fluid medicament. Therefore, the connector is such that there is fluid communication between the needle and the surgical instrument. In use, the invention needle is mounted on the distal tip of the surgical instrument, which is adapted to apply or transmit pressure to the medicament within the nonporous hollow shaft of the needle. The distal portion of the needle can be fabricated from any of a number of different "open cell" porous materials (i.e., materials in which the pores are interconnecting). For example, the distal portion can be fabricated from a porous sintered metal, such as forms a non-woven matrix of metal fibers selected from such metals as stainless steel, tantalum, elgiloy, nitinol, and the like, and suitable combinations of any two or more thereof. Generally, the metal fibers will have a diameter in the range from about 1.0 micron to about 25 microns . A non-woven matrix of metal fibers having these desired properties that can be used in manufacture of the porous distal portion of the invention needle is available from the Bekaeart Corporation (Marietta, GA), and is sold under the trademark, BEKIPOR® filter medium.
The distal porous portion of the needle can also be fabricated from such porous materials as a porous polymer, such as a porous polyimide, polyethylene, polypropylene, polytetrafluroethylene, and the like. Such porous polymers are disclosed, for example, in U.S. Patent No. 5,913,856, which is incorporated herein by reference in its entirety. Alternatively, a porous ceramic can be used, such as is known in the art for use in ceramic filters and separation membranes, or a porous metal (also known as an expanded metal) or carbon, such as is known in the art for use in filters or bone grafts. For example, Mott Corporation (Farmington, CT) manufactures porous metals for use in various types of filters.
If the porous filter medium is flexible, the distal portion of the invention needle can be fabricated by wrapping the filter medium, which is available commercially as a flat sheet, one or more times around an axis while creating a hollow central core. The porous distal portion of the needle can then be fused in fluid-tight fashion (e.g. welded) to a non-porous hollow needle shaft using methods known in the art. To create a porous portion of the needle having decreasing impedance to fluid flow, a porous filter medium or metal mesh having an appropriate porosity gradient can be employed in fabrication of the porous portion. Alternatively, a porous distal portion for the invention needle can be created from a non-porous material (e.g., a metal) using a cutting laser and techniques known in the art to punch pores into the needle segment (i.e. by a process of laser etching). For example, the nonporous hollow shaft, porous portion, and point of the invention needle can be fabricated of metal in a single piece, for example, from a conventional hypotube. In this scenario, a metal -cutting laser is used to create a segment of the needle that has appropriate porosity, for example, a porosity gradient within a portion of the needle as disclosed herein to equalize fluid impedance along the length of the porous portion of the needle.
In any event, the porosity of the distal portion is generally in the range from about 50% to about 85%, for example, at least about 70%.
Thus, the multidirectional flow of medicament from the needle is controlled by a number of factors, for example, the size, multiplicity and arrangement of the pores in the distal portion, the viscosity of the liquid medicament, the pressure applied to the medicament via the surgical instrument to which it is attached (i.e., the "injection pressure"), and the like. Those of skill in the art will know how to select and combine these factors to assure that the medicament weeps multidirectionally from the pores in the distal portion of the needle into tissue into which it is inserted without substantial surface leakage or tissue damage attributable to the injectate. For example, by balancing these factors, the flow of a liquid medicament from the needle can be adjusted to be at a rate slow enough for the injectate to be absorbed into tissue in the injection site without substantial disruption of cellular and membrane structures as would be caused by bolus or rapid injection, especially from a needle having a single opening. A rate of injection in the range from about 0.1 cc per second to about 2.0 cc per second, for example, from about 0.5 cc per second to about 1.0 cc per second is generally suitable to accomplish these goals.
In the embodiment of the invention illustrated in Figure 1 herein, needle 2 has a nonporous hollow needle shaft, a porous distal portion 6 having inter-connecting pores and a closed sharp tip 8. Injectate 12 oozes from the pores in the distal portion under injection pressure. The sharp tip 8 of needle 2 is closed so that no injectate flows from the point of the needle. The proximal end of needle 2 is fitted with flange 10 for removable attachment to a catheter. The distal end of catheter 16, which has at least one open lumen 14 for passage of injectate into needle 2 attaches to the proximal end of needle 2. In other embodiments, a hub for mating with a syringe is substituted for the flange at the proximal end of the needle.
In another embodiment according to the present invention, the invention needle further comprises one or more sensor connectors for electrical attachment to an electrocardiogram. The electrocardiogram can be used to determine contact between the needle tip and the tissue, or if multiple electrodes are present, to determine the depth of penetration. In the embodiment shown in Figure 2, the exterior of the needle shaft (not visible in this Figure) is coated with an insulator 18 and the connector 19 is attached directly to the proximal end (uncoated) of the needle shaft. Electrical lead 20 can be threaded down the lumen of a catheter for attachment to an electrocardiogram. Multiple leads can also be used in order to determine depth of the needle. In this configuration, the electrocardiogram is recorded from all leads. The larger signal is present from those ECG leads that are intramyocardial. Alternatively, the connector can be attached to the interior of the tip of the needle with an insulated connecting wire running down the hollow interior of the needle and catheter for attachment to an electrocardiogram. In this embodiment the needle itself acts as the electrode for the electrocardiogram and can be used for monopolar sensing of electrical currents or impedance within the heart, brain, nerves, proximal arteries, and the like.
For bipolar sensing a return electrode can be provided by placing an ECG pad in electrical connection with the electrocardiogram on the exterior of the patient, for example on the exterior of the chest wall. It is also contemplated within the scope of the invention that a second electrode or sensor connector can be attached to the needle, for example to the exterior of the needle, spaced apart from the first electrode by at least about 0.5 mm, so as to provide two electrodes for sensing electrical currents within a subject's bodily organs. It is also possible that an electrode permanently implanted in a subject, such as belongs to a pacemaker, can be used as the return lead for remote bipolar sensing.
The advantages of using the invention needles to perform sensing are several. For example, for injection into a muscle or other organ that has electrical impulses running through it, an electrocardiogram sensor attached to the invention needle can be used to confirm contact of the needle tip or proper insertion of the needle into the body wall of interest (e.g., the wall of a beating heart) before injection of the medicament into a treatment site. The depth of needle insertion into the tissue is determined by an array of electrodes. Those of skill in the art will realize that the invention needle having attached electrocardiogram sensor can also be used to judge whether such a prospective injection site is electrically active or not (i.e., whether the tissue is dead, hibernating due to lack of oxygen, or alive), and the like.
In another embodiment according to the present invention, there are provided surgical assemblages useful for microinjection of a liquid medicament into a remote location in a subject in need thereof. The invention surgical assemblage comprises a needle with a sharp distal point, and a catheter with a porous distal portion attached to the distal end of the needle, wherein the porous distal portion is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while the porous distal portion of the catheter is inserted into a body surface. The catheter in the invention surgical assemblage can be a steerable catheter having a steering mechanism at the handle for controlling deflection of the distal tip section of the catheter shaft, thereby, in effect, creating a "steerable needle."
Alternatively, the invention surgical assemblage can further comprise a guidance catheter of the type known in the art for guiding instruments used in angioplasty, as is described more fully hereinabove. In this embodiment, the needle and catheter with porous distal portion is introduced into (i.e., threaded through) the guidance catheter so that the needle and catheter with porous distal portion can be directed to the site of injection (e.g., threaded through a desired section of tissue) using the steerable guidance catheter. Preferably, the porous distal portion of the catheter is made of a flexible porous polymer, such as a porous polyimide, polyethylene, polytetrafluoroethylene, or polypropylene, and the like. The porous distal portion may further have features that create increasing hydraulic impedance on injectate moving therethrough towards the needle, thereby causing uniform flow of the injectate therefrom along the length of the porous distal portion as the injectate moves therethrough towards the needle to offset the falling off of injection pressure on fluid as it moves towards the point of the device. The flexibility of the porous segment in the assemblage facilitates injection of medicaments along a non-linear path.
As with the porous portion of the invention surgical needle described above, the size, and/or number of pores in the porous portion of the catheter in the invention surgical assemblage can be selected to create any desired gradient of injectate along the course of the injection path. For example, the size, and/or number of pores can decrease along the length of the porous portion moving towards the connection with the n edle to allow for a substantially uniform rate of injectate weepage along the length of the porous portion. In this configuration, therefore, once the needle is used to thread the porous portion of the catheter through the tissue to be treated, a substantially uniform rate of fluid weepage into surrounding tissues can be obtained along the injection course. Alternatively, or in conjunction with such a porosity gradient, the porous distal portion can also have a decreasing interior diameter along its length moving from the proximal end towards the connection with the needle to accomplish the same goal.
Figure 3 herein illustrates the invention surgical assemblage 22. Non-porous needle 24 with a closed tip is attached to the distal end of flexible catheter 26, which has a porous distal portion 28. Injectate 30 weeps from the pores in the flexible distal portion 28 of catheter 26.
In another embodiment according to the present invention, there are provided methods for injecting a medicament into an body wall in a subject in need thereof. The invention method comprises inserting the porous distal portion of the invention needle into the tissue of the subject and applying sufficient injection pressure to a liquid medicament in fluid communication with the porous distal portion of the needle to cause the medicament to ooze multidirectionally from the pores in the needle into the tissue. Alternatively, the invention surgical assembly, wherein the porous portion is not contained in the needle, but is a porous distal portion of an otherwise nonporous catheter, can be used in the invention injection methods to similar effect. If the point and porous portion of the needle or surgical assembly are inserted into the tissue before the medicament is injected, the injection of medicament is performed without substantial leakage or loss of medicament at the surface of the tissue or interior body wall.
As used herein, the term "medicament(s)" includes all types of liquid substances (e.g., including solutions and suspensions) that have a beneficial or therapeutic effect. Non-limiting examples of medicaments suitable for use in the invention methods include biologically active agents, such as small molecule drugs, proteinaceous substances, polynucleotides or nucleic acids (e.g. heterologous DNA, or RNA) and vectors, liposomes, and the like, containing such nucleic acids or polynucleotides, as well as liquid preparations or formulations thereof.
The invention methods and devices are designed for injection of minute amounts of fluid medicaments into tissue or a body wall, for example, an interior body wall. Hence the use of the term "microinjection" herein. For example, the therapeutic amount of the medicament to be administered according to the invention method will vary depending upon the therapeutic goal to be accomplished, the size and age of the subject, the pharmacokinetics of the injectate, and the like. However, a therapeutic amount according to the present invention is typically in the range from about 0.5 cc to about 2.0 cc.
Under injection pressure exerted upon a fluid medicament within the invention needle or surgical assemblage, the injectate will weep or ooze multidirectionally from the porous distal portion into surrounding tissue into which it is inserted, but should be prevented from exiting from the proximal portions of the invention devices. Flow of the injectate into the surrounding tissue is contemplated to be at a slow rate, for example, in the range from about 0.1 cc per second to about 2.0 cc per second to allow absorption of and dissipation the medicament into the tissue without substantial tissue damage caused by the injectate, (e.g., pooling of the medicament is thereby avoided). So long as the injectate contains no particles (e.g. cells) larger than the pores in the distal portion of the needle, overall flow of the medicament into tissue will be proportional to the amount of pressure applied on the injectate.
However, unless the porous portion of the invention device is adapted to cause a increasing gradient of impedance to fluid flow as the fluid moves distally through the porous portion (i.e., towards the point of the needle), the medicament will not weep at a uniform flow rate along the length of the porous portion.
In practice of the invention methods, it is presently preferred that the combination of the needle and the surgical instrument to which it is attached be selected so that the amount of the medicament that oozes from the pores of the needle can be controlled by the operator. For example, if a measured amount of the medicament is placed for delivery into a calibrated chamber of the surgical instrument and/or hollow of the needle, pressure on the medicament in the chamber sufficient to deliver 2 cc of the medicament from the pores of the distal portion of the needle while the distal portion is inserted into tissue of the subject will substantially assure that the subject receives 2 cc of the medicament. This feature of the invention devices and methods is particularly advantageous when it is important to closely monitor the amount of the medicament delivered to the subject, for example, to avoid waste of the medicament, to accurately judge the efficacy of the treatment, and the like.
The invention methods can be used to deliver to a subject in need of gene therapy an therapeutic amount of a medicament containing an isolated therapeutic nucleic acid sequence, or a vector, Hposome, or cell, and the like, containing such a nucleic acid sequence operatively associated with regulatory nucleic acid for expression of the encoded therapeutic protein. The invention devices and methods can be used to promote gene therapy by injection of such medicaments even when the injection site is located internally and/or is in constant motion. Therefore, in another embodiment according to the present invention, there are provided methods for injecting a therapeutic amount of a medicament into an interior body wall or tissue of a subject in need thereof. In this embodiment, the invention method comprises inserting the distal portion of the invention needle into an interior body wall or tissue of the subject and applying sufficient pressure to a liquid medicament in fluid communication with the distal portion of the needle to expel a therapeutic amount of the medicament such that the medicament weeps multidirectionally from the pores in the distal portion thereof into the interior body wall or tissue without substantial leakage or loss of the medicament at the surface of the body wall. The body wall can be located within a natural body cavity or a surgically created opening.
The invention method utilizing the needle with weeping tip is particularly useful for injection of medicaments into the wall of an interior organ that is subject to motion during the injection procedure, for example, the wall of a beating heart or adjacent arterial walls during electrophysiologic testing, transmyocardial revascularization, and the like. Additional internal organs subject to movement into which injections can be made using the invention methods include the stomach, esophagus, gallbladder, liver, bowel, kidney, lung, and the like.
By "isolated polynucleotide" or "isolated nucleic acid" or isolated nucleic acid sequence" is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g. a cDNA) independent of other sequences. Therapeutic nucleic acids contemplated fpr use in the practice of the present invention are intended to include those which encode products which are toxic to the cells in which they are expressed; those that encode products which impart a beneficial property to a subject; and those that transcribe nucleic acids which modulate transcription and/or translation of endogenous genes.
Preferred examples of suitable therapeutic nucleic acids for administration into cardiac tissues using the invention devices and methods include those encoding growth factors that enhance apoptosis and cell growth, such as bFGF (basic fibroblast growth factor, also known as FGF-2), aFGF (also known as FGF-1), EGF (epithelial growth factor), VEGF (vascular epithelial growth factor), angiostatin, ecchystatin, IGFs (insulin-like growth factors), and the like. These agents can be used to enhance or prevent the development of new blood vessels, prevent inflammation (as results from direct injection into the wall of an artery), prevent neointimal hyperplasia, or enhance or prevent the growth of new myocardial cells.
Additional therapeutic nucleic acids useful in the practice of the present invention include genes that encode biologically active proteins of interest, such as, e.g., secretory proteins that can be released from said cell; enzymes that can metabolize a toxic substance to produce a non-toxic substance, or that metabolize an inactive substance to produce a useful substance; regulatory proteins; cell surface receptors; and the like. Useful genes include genes that encode blood clotting factors, such as human factors VIII and IX; genes that encode hormones, such as insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), alpha and beta seminal inhibins, and human growth hormone; genes that encode proteins, such as enzymes, the absence of which leads to the occurrence of an abnormal state; genes encoding cytokines or lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as alphai-antitrypsin; genes encoding substances that function as drugs, e.g., genes encoding the diphtheria and cholera toxins; and the like.
Typically, nucleic acid sequence information for proteins encoded by therapeutic nucleic acid(s) contemplated for use employed herein can be located in one of many public access databases, e.g., GENBANK, EMBL, Swiss-Prot, and PIR, or in related journal publications. Thus, those of skill in the art have access to sequence information for virtually all known genes. Those of skill in the art can obtain the corresponding nucleic acid molecule directly from a public depository or from the institution that published the sequence. Optionally, once the nucleic acid sequence encoding a desired protein has been ascertained, the skilled artisan can employ routine methods, e.g., polymerase chain reaction (PCR) amplification, to isolate the desired nucleic acid molecule from the appropriate nucleic acid library. Thus, all known nucleic acids encoding proteins of interest are available for use in the methods and products described herein.
Additional components that can optionally be incorporated into the invention constructs include selectable markers and genes encoding proteins required for retroviral packaging, e.g., thepo/ gene, the gag gene, the env gene, and the like.
Selectable markers contemplated for use in the practice of the present invention include antibiotic resistance genes, genes that enable cells to process metabolic
J intermediaries, and the like. Exemplary antibiotic resistance genes include genes which impart tetracycline resistance, genes that impart ampicillin resistance, neomycin resistance, hygromycin resistance, puromycin resistance, and the like.
Optionally, the cells can be obtained from the subject or host (i.e., rather than a donor), modified as above, and then reintroduced into the subject using the invention devices and methods. For example, therapeutic nucleic acid can be introduced directly into cells obtained from a subject and the modified cells can be then injected into the subject.. The therapeutic nucleic acid may be stably incorporated into cells or may be transiently expressed using methods known in the art.
Modified cells are cultivated under growth conditions (as opposed to protein expression conditions) until a desired density is achieved. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene (such as the E. coli β- galactosidase gene) to monitor transfection efficiency. Selectable marker genes are typically not included in the transient transfections because the transfectants are typically not grown under selective conditions, and are usually analyzed within a few days after transfection.
The concept of gene replacement therapy for humans involves the introduction of functionally active nucleic acids into the somatic cells of an affected subject to correct a gene defect or deficiency. Genes that encode useful "gene therapy" proteins that are not normally transported outside the cell can be used in the invention if such genes are "functionally appended" to, or operatively associated with, a signal sequence that can "transport" the encoded product across the cell membrane. A variety of such signal sequences are known and can be used by those skilled in the art without undue experimentation.
Regulatory elements employed in the practice of the present invention are operably linked to a suitable promoter for transcription of therapeutic nucleic acid product(s). As used herein, the term "promoter" refers to a specific nucleic acid sequence recognized by RNA polymerase, the enzyme that initiates RNA synthesis. The promoter sequence is the site at which transcription can be specifically initiated under proper conditions. When exogenous nucleic acid(s), operatively linked to a suitable promoter, are introduced into the cells of a suitable host, expression of the exogenous nucleic acid(s) can be controlled in many, but not all cases, by the presence of ligands, which are not normally present in the host cells.
Promoters contemplated for control of expression of exogenous nucleic acids employed in the practice of the present invention include inducible (e.g., minimal CMV promoter, minimal TK promoter, modified MMLV LTR), constitutive (e.g., chicken β- actin promoter, MMLV LTR (non-modified), DHFR), and/or tissue specific promoters. Inducible promoters contemplated for use in the practice of the present invention comprise transcription regulatory regions that function maximally to promote transcription of mRNA under inducing conditions. Examples of suitable inducible promoters include DNA sequences corresponding to: the E. coli lac operator responsive to IPTG (see Nakamura et al. , Cell, 18: 1109- 1117, 1979); the metallothionein promoter metal-regulatory-elements responsive to heavy-metal (e.g., zinc) induction (see Evans et al, U.S. Patent No. 4,870,009), the phage T71ac promoter responsive to IPTG (see Studier et al, Meth. Enzymol, 185: 60-89, 1990; and U.S. Patent No. 4,952,496), the heat-shock promoter; the TK minimal promoter; the CMV minimal promoter; a synthetic promoter; and the like.
Exemplary constitutive promoters contemplated for use in the practice of the present invention include the CMV promoter, the SV40 promoter, the DHFR promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, elongation factor 1 a (EF 1 a) promoter, albumin promoter, APO Al promoter, cyclic AMP dependent kinase II (CaMKII) promoter, keratin promoter, CD3 promoter, immunoglobulin light or heavy chain promoters, neurofiliment promoter, neuron specific enolase promoter, L7 promoter, CD2 promoter, myosin light chain kinase promoter, HOX gene promoter, thymidine kinase (TK) promoter, RNA Pol II promoter, MYOD promoter, MYF5 promoter, phosphoglycerokinase (PGK) promoter, Stfl promoter, Low Density Lipoprotein (LDL) promoter, chicken β-actin promoter (e.g., used in conjunction with an ecdysone response element), and the like.
As readily understood by those of skill in the art, the term "tissue specific" refers to the substantially exclusive initiation of transcription in the tissue from which a particular promoter that drives expression of a given gene is derived (e.g., expressed only in T-cells, endothelial cells, smooth muscle cells, and the like). Exemplary tissue specific promoters contemplated for use in the practice of the present invention include the GH promoter, the NSE promoter, the GFAP promoter, neurotransmitter promoters (e.g., tyrosine hydroxylase, TH, choline acetyltransferase, ChAT, and the like), promoters for neurotropic factors (e.g., a nerve growth factor promoter, NT-3, BDNF promoters, and the like), and so on.
As used herein, the phrase "operatively associated with" refers to the functional relationship of DNA with regulatory and effector sequences of nucleic acids, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.
Gene transfer vectors (also referred to as "expression vectors") contemplated for use herein are recombinant nucleic acid molecules that are used to transport nucleic acid into host cells for expression and/or replication thereof. Expression vectors may be either circular or linear, and are capable of incorporating a variety of nucleic acid constructs therein. Expression vectors typically come in the form of a plasmid that, upon introduction into an appropriate host cell, results in expression of the inserted nucleic acid.
Suitable expression vectors for use herein are well known to those of skill in the art and include recombinant DNA or RNA construct(s), such as plasmids, phage, recombinant virus or other vectors that, upon introduction into an appropriate host cell, result(s) in expression of the inserted DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. Expression vectors typically further contain other functionally important nucleic acid sequences encoding antibiotic resistance proteins, and the like.
The amount of therapeutic nucleic acid introduced into a subject can be varied by those of skill in the art. For example, when a viral vector is employed to achieve gene transfer, the amount of nucleic acid introduced can be varied by varying the amount of plaque forming units (PFU) of the viral vector. Exemplary eukaryotic expression vectors include eukaryotic constructs, such as the pSV-2 gpt system (Mulligan et al, Nature 212:108-114, 1979); pBlueSkript (Stratagene, La Jolla, CA), the expression cloning vector described by Genetics Institute (Science 228:810-815. 1985), and the like. Each of these plasmid vectors is capable of promoting expression of the protein product of the nucleic acid of interest.
Suitable means for introducing (transducing) expression vectors containing therapeutic nucleic acid constructs into cells of a subject treated according to the invention methods include infection employing viral vectors (see, e.g., U.S. Patent
4,405,712 and 4,650,764). The transduced nucleic acid can optionally include sequences which allow for its extrachromosomal (i.e., episomal) maintenance, or the transduced nucleic acid can be donor nucleic acid that integrates into the genome of the host.
In a specific embodiment, a gene transfer vector contemplated for use herein is a viral vector, such as Adenovirus, adeno-associated virus, a herpes-simplex virus based vector, a synthetic vector for gene therapy, and the like (see, e.g., Suhr et al. Arch. of Neurol. 5_0_: 1252-1268, 1993). Preferably, a gene transfer vector employed herein is a retroviral vector. Retroviral vectors contemplated for use herein are gene transfer plasmids that have an expression construct containing an exogenous nucleic acid residing between two retroviral LTRs. Retroviral vectors typically contain appropriate packaging signals that enable the retroviral vector, or RNA transcribed using the retroviral vector as a template, to be packaged into a viral virion in an appropriate packaging cell line (see, e.g., U.S. Patent 4,650,764).
Suitable retroviral vectors for use herein are described, for example, in U.S. Patents 5,399,346 and 5,252,479; and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, each of which is hereby incorporated herein by reference, in its entirety. These documents provide a description of methods for efficiently introducing nucleic acids into human cells using such retroviral vectors. Other retroviral vectors include, for example, mouse mammary tumor virus vectors (e.g., Shackleford et alPNAS, USA, 85:9655-9659, 1988), human immunodeficiency virus (e.g., Naldini et al. Science 222:165-320, 1996), and the like.
Various procedures are also well-known in the art for providing helper cells which produce retroviral vector particles that are essentially free of replicating virus. See, for example, U.S. Patent 4,650,764; Miller, Human Gene Therapy, 1:5-14, 1990; Markowitz, et al, Journal of Virology, 6_K4):1120-1124, 1988; Watanabe, et al, Molecular and Cellular Biology, 3_02):2241-2249, 1983; Danos, et al, PNAS, £5:6460- 6464, 1988; and Bosselman, et al. , Molecular and Cellular Biology, 5): 1797-1806, 1987, which disclose procedures for producing viral vectors and helper cells that minimize the chances for producing a viral vector that includes a replicating virus.
Recombinant retroviruses suitable for carrying out the invention methods are produced employing well-known methods for producing retroviral virions. See, for example, U.S. Patent 4,650,764; /7/er, supra 1990; Markowitz, et al, supra 1988;
Watanabe, et al, supra 1983; Danos, et al, PNAS, £5_:6460-6464, 1988; and Bosselman, et al, "Molecular and Cellular Biology, 7_(5J: 1797-1806, 1987.
By introducing all of the necessary regulatory machinery, plus exogenous nucleic acid, selectable markers, and nucleic acid encoding invention chimeric protein, e.g., into a MARV retrovirus, highly efficient insertion of exogenous nucleic acids into targeted cells can be achieved.
Thus, the above-described viral constructs address several important problems confronted in the use of retroviruses in application of therapeutic gene transfer strategies to a variety of human diseases. For example, the retroviral vectors of the invention are capable of prolonged gene expression under conditions where conventionally integrated retroviruses are no longer transcriptionally active.
As used herein, when referring to nucleic acids, the phrase "exogenous to said mammalian host" or simply "exogenous" refers to nucleic acids not naturally found at levels sufficient to provide a function in the particular cell where transcription is desired. For example, exogenous nucleic acids can be either natural or synthetic nucleic acids, which are introduced into the subject in the form of DNA or RNA. The nucleic acids of interest can be introduced directly or indirectly into a subject, for example, by the transfer of transformed cells into a subject using invention methods.
As employed herein, the terms "subject" and "hosf'refer to a mammalian patient in need of administration of a medicament. The subject mammals include: humans; domesticated animals, e.g., rat, mouse, rabbit, canine, feline, and the like; farm animals, e.g., chicken, bovine, ovine, porcine, and the like; animals of zoological interest, e.g., monkey, baboon, and the like
While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

Claims

WHAT IS CLAIMED IS:
1. A surgical needle comprising: a nonporous hollow needle shaft having a proximal end adapted to mate with a surgical instrument, a porous distal portion in fluid-tight connection to the needle shaft, and a point that is open, closed, or has a solid partial plug, wherein the porous distal portion is adapted to cause a liquid injectate to weep or ooze therefrom multidirectionally under injection pressure while the point and distal portion of the needle are inserted into a body surface.
2. The needle according to claim 1 wherein the porous distal portion has pores with an average largest dimension in the range from about 1.0 micron to about 200 microns .
3. The needle according to claim 1 wherein the porous distal portion creates a gradient of hydraulic impedance on injectate moving therethrough towards the point.
4. The needle according to claim 3 wherein the gradient is linear, exponential or Gaussian in either longitudinal direction.
5. The needle according to claim 3 wherein the gradient is a decreasing gradient.
6. The needle according to claim 3 wherein the porous distal portion has a increasing interior diameter along the length thereof from the proximal end to the point.
7. The needle according to claim 3 wherein the size and/or number of the pores in the porous distal portion increases along the length thereof from the proximal end to the point.
8. The needle according to claim 1 wherein at least the porous distal portion is fabricated from a porous carbon, metal, ceramic, or polymer.
9. The needle according to claim 8 wherein the porous distal portion is fabricated from a porous metal.
10. The needle according to claim 8 wherein the porous distal portion is fabricated from a porous polymer
11. The needle according to claim 8 wherein the porous distal portion is fabricated from a porous carbon or ceramic.
12. The needle according to claim 1 wherein the porous distal portion has a porosity of about 50% to about 85%.
13. The needle according to claim 1 wherein flow of a liquid from the needle is in
J the range from about 0.1 cc/sec to about 2.0 cc/sec.
14. The needle according to claim 1 wherein the surgical instrument is a catheter.
15. The needle according to claim 14 wherein the catheter is a steerable endoscopic catheter.
16. The needle according to claim 1 wherein the surgical instrument is a syringe.
17. The needle according to claim 1 wherein the needle further comprises one or more connectors for electrical attachment to an electrocardiogram.
18. The needle according to claim 17 wherein the exterior of the needle shaft is coated with an insulator and the connector is electrically connected to the proximal end of the needle shaft.
19. A method for injecting a medicament into tissue in a subject in need thereof, said method comprising: inserting the distal portion of the needle according to claim 1 into the tissue of the subject and causing a therapeutic amount of the medicament to ooze multidirectionally from the needle into the tissue without substantial leakage or loss of the medicament at the surface of the tissue.
20. The method according to claim 19 wherein the amount is from about 0.5 cc to about 2.0 cc of the medicament.
21. The method according to claim 19 wherein injection pressure is applied to the liquid medicament in fluid communication with the distal portion of the needle to cause a therapeutic amount of the medicament to ooze from the needle.
22. The method according to claim 19 wherein flow of the medicament from the needle is in the range from about 0.1 cc/sec to about 2.0 cc/sec.
23. The method according to claim 19 wherein the medicament comprises an isolated therapeutic nucleic acid sequence.
24. The method according to claim 23 wherein the nucleic acid sequence is contained within a vector, a Hposome, or a cell.
25. A method for injecting a medicament into a subject in need thereof, said method comprising: inserting the distal portion of the needle of claim 1 into an interior body wall or tissue of the subject and applying sufficient pressure to a liquid medicament in fluid communication with the distal portion of the needle to expel the medicament, whereby the medicament weeps multidirectionally from the pores in the distal portion into the interior body wall without substantial leakage or loss of the medicament at the surface of the tissue.
26. The method according to claim 25 wherein the flow of the medicament into the surrounding tissue is substantially equal along the length of the porous distal portion of the needle.
27. The method according to claim 25 wherein the needle is attached to a syringe.
28. The method according to claim 25 wherein the needle is attached to the distal tip of a catheter and the body wall is within a body cavity.
29. The method according to claim 28 wherein the catheter is a steerable catheter that is used to guide the needle to an injection site.
30. The method according to claim 28 wherein a guidance catheter is used to guide the needle and catheter with porous distal portion to an injection site.
31. The method according to claim 28 wherein the body cavity is surgically created.
32. The method according to claim 28 wherein the body wall is subject to motion.
33. The method according to claim 32 wherein the body wall is in a beating heart.
34. The method according to claim 25 wherein the needle further comprises at least one sensor in electrical connection to an electrocardiogram and the method further comprises sensing electrical activity in the body wall.
35. The method according to claim 34 wherein electrical activity is sensed prior to injection of the medicament.
36. The method according to claim 34 wherein the needle comprises multiple sensors and wherein the multiple sensors are used to determine the depth of needle penetration into the tissue of the subject before, during and/or after the injection of medicament.
37. The method according to claim 25 wherein the body wall is in a beating heart.
38. The method according to claim 25 wherein the body wall is within an artery.
39. The method according to claim 25 wherein the medicament comprises a isolated therapeutic nucleic acid sequence.
40. The method according to claim 39 wherein the nucleic acid sequence is contained within a vector, Hposome, or cell.
41. The method according to claim 39 wherein the therapeutic nucleic acid sequence encodes bFGF, aFGF, EGF, VEGF, angiostatin, ecchystatin, or an IGF.
42. The method according to claim 41 wherein the therapeutic nucleic acid is contained within a viral vector.
43. The method according to claim 25 wherein the medicament comprises genetically engineered cells containing a isolated nucleic acid sequence that encodes a therapeutic gene product.
44. The method according to claim 40 wherein the cell is heterologous.
45. The method according to claim 39 wherein the cell is obtained from the subject.
46. A surgical assemblage comprising: a hypodermic needle with a sharp distal point that is open, closed, or has a solid partial plug, and a catheter with a porous distal portion attached to the distal end of the needle, wherein the porous distal portion is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while inserted into a body surface.
47. The assemblage according to claim 46 wherein the porous distal portion creates a gradient of hydraulic impedance on injectate moving therethrough in order to preferentially deliver agent at any longitudinal point longitudinally along the distal portion.
48. The assemblage according to claim 47 wherein the decrease in impedance is linear, exponential or Gaussian.
49. J The assemblage according to claim 46 wherein the needle has a length in the range from about 100 mm to about 1500 mm and the porous distal portion of the catheter has a length in the range from about 1mm to about 20 mm.
50. The assemblage according to claim 44 wherein the porous distal portion is made of a porous polymer.
51. A surgical assemblage comprising: a nonporous needle with a sharp distal point, said needle being adapted at the proximal end for attachment to the distal end of a catheter, and a catheter comprising a porous distal portion and a distal end that is adapted for attachment to the needle, wherein the porous distal portion is adapted to cause a liquid injectate to weep or ooze multidirectionally therefrom into surrounding tissue under injection pressure while the porous distal portion of the catheter is inserted into a body surface.
52. The assemblage according to claim 51 wherein the needle has a length in the range from about 10 mm to about 1500 mm and the porous distal portion has a length in the range from about 1mm to about 20 mm.
53. The assemblage according to claim 51 wherein the catheter is a steerable catheter.
54. The assemblage according to claim 51 further comprising a guidance catheter for receiving and steering the assembled needle and catheter with a porous distal portion to an injection site.
55. A method for preventing substantial tissue damage when injecting a medicament, said method comprising injecting the medicament from the distal portion of the needle of claim 1 into the subject so that the medicament weeps multidirectionally from the pores in the distal portion thereof without substantial damage to tissue of the subject caused by injectate.
PCT/US2000/034365 1999-12-20 2000-12-18 Surgical needle with weeping tip and method of use WO2001045548A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU22757/01A AU783463B2 (en) 1999-12-20 2000-12-18 Hypodermic needle with weeping tip and method of use
DE60033688T DE60033688T2 (en) 1999-12-20 2000-12-18 SURGICAL NEEDLE WITH TAMPERING TIP
JP2001546291A JP2003517863A (en) 1999-12-20 2000-12-18 Surgical needle with leaching tip and use thereof
CA002394860A CA2394860A1 (en) 1999-12-20 2000-12-18 Hypodermic needle with weeping tip and method of use
EP00986533A EP1239776B1 (en) 1999-12-20 2000-12-18 Surgical needle with weeping tip

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/468,688 1999-12-20
US09/468,688 US6241710B1 (en) 1999-12-20 1999-12-20 Hypodermic needle with weeping tip and method of use

Publications (2)

Publication Number Publication Date
WO2001045548A2 true WO2001045548A2 (en) 2001-06-28
WO2001045548A3 WO2001045548A3 (en) 2002-01-10

Family

ID=23860824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034365 WO2001045548A2 (en) 1999-12-20 2000-12-18 Surgical needle with weeping tip and method of use

Country Status (8)

Country Link
US (5) US6241710B1 (en)
EP (1) EP1239776B1 (en)
JP (1) JP2003517863A (en)
AT (1) ATE355018T1 (en)
AU (1) AU783463B2 (en)
CA (1) CA2394860A1 (en)
DE (1) DE60033688T2 (en)
WO (1) WO2001045548A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855124B1 (en) 2002-10-02 2005-02-15 Advanced Cardiovascular Systems, Inc. Flexible polymer needle catheter
JP2005534430A (en) * 2002-08-06 2005-11-17 ジェンベック, インコーポレイテッド Improved injection system
US7033345B2 (en) 2002-05-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Deflectable microimplant delivery system
EP1743674A2 (en) * 2002-09-18 2007-01-17 Cardiac Pacemakers, Inc. Device to stimulate therapeutic angiogenesis for ischemia and heart failure
WO2010125166A1 (en) 2009-04-29 2010-11-04 Cardio3 Biosciences Injection catheter for delivering a therapeutic agent into a substrate
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8500680B2 (en) 2002-06-28 2013-08-06 Abbott Cardiovascular Systems Inc. Device and method for combining a treatment agent and a gel
US8876792B2 (en) 2008-04-08 2014-11-04 Karolinska Institutet Innovations Ab Endoluminal medical access device
US9687630B2 (en) 2005-04-19 2017-06-27 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US9775930B2 (en) 2006-11-17 2017-10-03 Abbott Cardiovascular Systems Inc. Composition for modifying myocardial infarction expansion

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8079982B1 (en) 1998-06-04 2011-12-20 Biosense Webster, Inc. Injection catheter with needle electrode
US7416547B2 (en) * 1999-03-29 2008-08-26 Biosense Webster Inc. Injection catheter
US6623473B1 (en) * 1998-06-04 2003-09-23 Biosense Webster, Inc. Injection catheter with multi-directional delivery injection needle
US6623474B1 (en) * 1998-06-04 2003-09-23 Biosense Webster, Inc. Injection catheter with needle stop
US6905476B2 (en) * 1998-06-04 2005-06-14 Biosense Webster, Inc. Catheter with injection needle
US6440118B2 (en) * 1999-05-11 2002-08-27 Lawrence S. Burr Device and method to sense body substance transition
US6547561B2 (en) * 1999-06-09 2003-04-15 Tulsa Dental Products Inc. Disposable anesthesia delivery system with shortened outer sleeve and inner hollow drill
US6575745B2 (en) * 2000-12-05 2003-06-10 Tulsa Dental Products Inc. Titanium alloy intraosseous anesthesia delivery device
US6241710B1 (en) * 1999-12-20 2001-06-05 Tricardia Llc Hypodermic needle with weeping tip and method of use
US6945969B1 (en) 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US7807210B1 (en) * 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US6833153B1 (en) * 2000-10-31 2004-12-21 Advanced Cardiovascular Systems, Inc. Hemocompatible coatings on hydrophobic porous polymers
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8979801B2 (en) * 2001-01-17 2015-03-17 Medtronic Vascular, Inc. Microcatheter devices and methods for targeted substance delivery
US6969373B2 (en) * 2001-04-13 2005-11-29 Tricardia, Llc Syringe system
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
ATE485766T1 (en) 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US6749580B2 (en) 2001-10-05 2004-06-15 Medical Components, Inc. Catheter
US6911014B2 (en) * 2001-10-05 2005-06-28 Medical Components, Inc. Continuous flow peritoneal dialysis catheter
US8002775B2 (en) * 2001-10-24 2011-08-23 Warsaw Orthopedic, Inc. Methods and instruments for treating pseudoarthrosis
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US20040054334A1 (en) * 2001-12-28 2004-03-18 Prais Alfred W. Medical needle assemblies
US20030125677A1 (en) * 2001-12-28 2003-07-03 Becton, Dickinson And Company Medical needle assemblies
US6730059B2 (en) 2001-12-28 2004-05-04 Becton, Dickinson And Company Medical needle assemblies
US6726649B2 (en) * 2001-12-28 2004-04-27 Becton, Dickinson And Company Medical needle assemblies
US20030121812A1 (en) * 2001-12-28 2003-07-03 Sprieck Terry L. Medical needle assemblies
US20040039340A1 (en) * 2001-12-28 2004-02-26 Becton, Dickinson And Company Shieldable unit dose medical needle assemblies
US6878136B2 (en) 2002-02-28 2005-04-12 Medical Product Specialists Huber needle with anti-rebound safety mechanism
US20040082922A1 (en) * 2002-02-28 2004-04-29 Fleury Michael T. Huber needle with anti-rebound safety mechanism
US6918894B2 (en) 2002-02-28 2005-07-19 Medical Product Specialists Huber needle with anti-rebound safety mechanism
US20050027264A1 (en) 2002-02-28 2005-02-03 Fleury Michael T. Huber needle with anti-rebound safety mechanism
GB0208627D0 (en) * 2002-04-16 2002-05-22 Imprint Pharm Ltd Needle
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
DE60314157T2 (en) * 2002-09-10 2008-01-31 Becton Dickinson And Co. METHOD AND DEVICE FOR THE EPIDERMIC ADMINISTRATION OF A SUBSTANCE
US7294132B2 (en) * 2002-10-03 2007-11-13 Wright Medical Technology, Inc. Radially ported needle for delivering bone graft material and method of use
US7326196B2 (en) * 2002-10-14 2008-02-05 Breg, Inc. Catheter assemblies for controlled movement of fluid
US8336596B2 (en) 2002-11-22 2012-12-25 The Boeing Company Composite lamination using array of parallel material dispensing heads
US7137182B2 (en) * 2002-11-22 2006-11-21 The Boeing Company Parallel configuration composite material fabricator
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US20040147881A1 (en) * 2003-01-24 2004-07-29 Hyun Dongchul D. Huber needle with a manually movable sleeve member for containing its injection point
US20060200128A1 (en) * 2003-04-04 2006-09-07 Richard Mueller Bone anchor
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
EP1475113A1 (en) * 2003-05-08 2004-11-10 Novo Nordisk A/S External needle inserter
ATE392223T1 (en) 2003-05-08 2008-05-15 Novo Nordisk As INTERNAL NEEDLE INTRODUCER
ATE474611T1 (en) 2003-05-08 2010-08-15 Novo Nordisk As AN INJECTION DEVICE THAT CAN BE APPLIED TO THE SKIN WITH A SEPARABLE ACTUATING PART FOR INSERTING THE NEEDLE
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7236625B2 (en) 2003-07-28 2007-06-26 The Boeing Company Systems and method for identifying foreign objects and debris (FOD) and defects during fabrication of a composite structure
EP1502613A1 (en) 2003-08-01 2005-02-02 Novo Nordisk A/S Needle device with retraction means
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
US7481826B2 (en) * 2003-09-30 2009-01-27 Ethicon, Inc. Fluid emitting suture needle
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US20050080410A1 (en) * 2003-10-14 2005-04-14 Scimed Life Systems, Inc. Liquid infusion apparatus for radiofrequency tissue ablation
WO2005049110A2 (en) * 2003-11-15 2005-06-02 Medrad, Inc. Catheter for diagnostic imaging and therapeutic procedures
US8934702B2 (en) * 2003-12-02 2015-01-13 The Boeing Company System and method for determining cumulative tow gap width
US7289656B2 (en) 2003-12-02 2007-10-30 The Boeing Company Systems and methods for determining inconsistency characteristics of a composite structure
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US7282051B2 (en) * 2004-02-04 2007-10-16 Boston Scientific Scimed, Inc. Ablation probe for delivering fluid through porous structure
US20050187525A1 (en) * 2004-02-19 2005-08-25 Hilgers Michael E. Devices and methods for extracting bodily fluid
US7039485B2 (en) 2004-03-12 2006-05-02 The Boeing Company Systems and methods enabling automated return to and/or repair of defects with a material placement machine
CN100586495C (en) 2004-03-30 2010-02-03 诺和诺德公司 Actuator system comprising lever mechanism
US7193696B2 (en) * 2004-04-12 2007-03-20 United Technologies Corporation Systems and methods for using light to indicate defect locations on a composite structure
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2006032692A1 (en) 2004-09-22 2006-03-30 Novo Nordisk A/S Medical device with cannula inserter
US7325771B2 (en) 2004-09-23 2008-02-05 The Boeing Company Splice joints for composite aircraft fuselages and other structures
US7424902B2 (en) * 2004-11-24 2008-09-16 The Boeing Company In-process vision detection of flaw and FOD characteristics
US20060108048A1 (en) 2004-11-24 2006-05-25 The Boeing Company In-process vision detection of flaws and fod by back field illumination
MX2007006975A (en) 2004-12-09 2007-08-15 West Pharm Serv Inc Breech loaded fixed needle syringe and automatic injection device having the same.
JP4576222B2 (en) * 2004-12-17 2010-11-04 日機装株式会社 In vivo characteristic sensor and biological information monitoring system
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7889907B2 (en) 2005-01-12 2011-02-15 The Boeing Company Apparatus and methods for inspecting tape lamination
EP1848476A1 (en) 2005-01-24 2007-10-31 Novo Nordisk A/S Transcutaneous device assembly
US7803142B2 (en) 2005-02-02 2010-09-28 Summit Access Llc Microtaper needle and method of use
US7722558B2 (en) * 2005-02-15 2010-05-25 Ott Douglas E Trocar sleeve for jet stream condition
JP2006271651A (en) * 2005-03-29 2006-10-12 Matsumoto Shika Univ Needle component for liquid injection, and production method thereof
US20060229573A1 (en) * 2005-04-08 2006-10-12 Mckinley Medical L.L.L.P. Adjustable infusion catheter
US8235719B2 (en) 2005-04-13 2012-08-07 Endo Inventions, Llc Apparatus for cleaning a root canal system
US20060234182A1 (en) * 2005-04-13 2006-10-19 Ruddle Clifford J Apparatus for cleaning a root canal system
US8388345B2 (en) * 2005-04-13 2013-03-05 Clifford J. Ruddle Method for cleaning a root canal system
EP1877116A1 (en) 2005-04-13 2008-01-16 Novo Nordisk A/S Medical skin mountable device and system
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US7850656B2 (en) * 2005-04-29 2010-12-14 Warsaw Orthopedic, Inc. Devices and methods for delivering medical agents
US8083722B2 (en) * 2005-04-29 2011-12-27 Warsaw Orthopedic, Inc Instrumentation for injection of therapeutic fluid into joints
JP4759051B2 (en) * 2005-06-07 2011-08-31 フレックス パートナーズ インコーポレイテッド System and method for restoring nutrient flow to the nucleus pulposus
JP5058998B2 (en) 2005-07-18 2012-10-24 ウェスト ファーマシューティカル サービシズ インコーポレイテッド Automatic injection syringe with venting means
WO2007013065A2 (en) 2005-07-25 2007-02-01 Rainbow Medical Ltd. Electrical stimulation of blood vessels
US7435947B2 (en) * 2005-10-31 2008-10-14 The Boeing Company Apparatus and methods for integrating encoding functions in material placement machines
US7372556B2 (en) * 2005-10-31 2008-05-13 The Boeing Company Apparatus and methods for inspecting a composite structure for inconsistencies
US7713232B2 (en) * 2005-11-04 2010-05-11 Medrad, Inc. System for washing and processing of cells for delivery thereof to tissue
US8182444B2 (en) * 2005-11-04 2012-05-22 Medrad, Inc. Delivery of agents such as cells to tissue
US8251963B2 (en) * 2005-12-08 2012-08-28 Boston Scientific Scimed, Inc. Flexible needle
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
WO2007104755A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Secure pairing of electronic devices using dual means of communication
US9399094B2 (en) 2006-06-06 2016-07-26 Novo Nordisk A/S Assembly comprising skin-mountable device and packaging therefore
US7935092B1 (en) 2006-07-25 2011-05-03 Twin Star Medical, Inc. Self-introducing injection and aspiration device
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
EP2073884B1 (en) 2006-08-02 2018-10-10 Osprey Medical Inc. Microvascular obstruction detection and therapy
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8876754B2 (en) * 2006-08-31 2014-11-04 Bayer Medical Care Inc. Catheter with filtering and sensing elements
US8377005B2 (en) 2006-09-11 2013-02-19 Custom Medical Applications Neural injection system and related methods
US9480800B2 (en) 2006-09-11 2016-11-01 Custom Medical Applications Neural injection system and related methods
US20080065029A1 (en) * 2006-09-11 2008-03-13 Racz N S Nerve block needle and related methods
US9888940B2 (en) 2006-09-11 2018-02-13 Custom Medical Applications Neural injection system and related methods
US8449503B2 (en) 2010-11-30 2013-05-28 Custom Medical Applications Neural injection system and related methods
US20080086111A1 (en) * 2006-10-09 2008-04-10 Medrad, Inc. Fluid delivery systems and volume metering in cell delivery
US7931651B2 (en) * 2006-11-17 2011-04-26 Wake Lake University Health Sciences External fixation assembly and method of use
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
WO2008067362A2 (en) * 2006-11-28 2008-06-05 Medrad, Inc. Multiple lumen diffusion catheter
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8690832B2 (en) * 2007-06-13 2014-04-08 Custom Medical Applications Retrofitted neural injection system and related methods
US9131960B2 (en) 2007-06-13 2015-09-15 Custom Medical Applications Safety neural injection system and related methods
JP2009052016A (en) * 2007-07-27 2009-03-12 Fujifilm Corp Composition, molded product, its manufacturing method, film and its manufacturing method
EP2209500B1 (en) 2007-10-31 2015-07-22 Novo Nordisk A/S Non-porous material as sterilization barrier
US9510885B2 (en) 2007-11-16 2016-12-06 Osseon Llc Steerable and curvable cavity creation system
US20090131867A1 (en) 2007-11-16 2009-05-21 Liu Y King Steerable vertebroplasty system with cavity creation element
US20090131886A1 (en) * 2007-11-16 2009-05-21 Liu Y King Steerable vertebroplasty system
US20100305392A1 (en) * 2008-01-31 2010-12-02 Enopace Biomedical Ltd. Thoracic aorta and vagus nerve stimulation
US8538535B2 (en) 2010-08-05 2013-09-17 Rainbow Medical Ltd. Enhancing perfusion by contraction
US9005106B2 (en) 2008-01-31 2015-04-14 Enopace Biomedical Ltd Intra-aortic electrical counterpulsation
DE102008013854A1 (en) * 2008-03-12 2009-09-24 Siemens Aktiengesellschaft Catheter and associated medical examination and treatment facility
US9364634B2 (en) 2008-04-22 2016-06-14 Becton, Dickinson And Company Systems and methods for improving catheter hole array efficiency
US8496629B2 (en) 2008-04-22 2013-07-30 Becton, Dickinson And Company Catheter hole having a flow breaking feature
US9399112B2 (en) 2008-04-22 2016-07-26 Becton, Dickinson And Company Catheter hole having an inclined trailing edge
US8403911B2 (en) * 2008-04-22 2013-03-26 Becton, Dickinson And Company Systems and methods for improving catheter hole array efficiency
US8974411B2 (en) * 2008-05-21 2015-03-10 Becton, Dickinson And Company Conical diffuser tip
EP2310070A1 (en) * 2008-07-09 2011-04-20 Grantadler Corporation Needle for subcutaneous port
KR20110070976A (en) 2008-07-18 2011-06-27 웨이크 포리스트 유니버시티 헬스 사이언시즈 Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage
US20100130958A1 (en) * 2008-11-26 2010-05-27 David Kang Device and Methods for Subcutaneous Delivery of High Viscosity Fluids
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9072296B2 (en) 2009-03-26 2015-07-07 Organic Medical Ventures, L.L.C. Transdermal venous access locking solutions
US9427498B2 (en) 2009-03-26 2016-08-30 Organic Medical Ventures, L.L.C. Syringe treated with transdermal venous access locking solutions and method of treating the syringe
US9433209B2 (en) 2009-03-26 2016-09-06 Organic Medical Ventures, L.L.C. Transdermal venous access locking solutions
US20100249747A1 (en) * 2009-03-26 2010-09-30 Organic Medical Ventures, L.L.C. Transdermal venous access locking solution
US9393382B2 (en) * 2009-05-05 2016-07-19 Robert W. Heck High-flow tapered peripheral IV catheter with side outlets
US20100298832A1 (en) 2009-05-20 2010-11-25 Osseon Therapeutics, Inc. Steerable curvable vertebroplasty drill
WO2011011436A2 (en) 2009-07-21 2011-01-27 The General Hospital Corporation D/B/A Peripheral blood sampling methods and devices
US20110028981A1 (en) * 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. Bone graft measuring apparatus and method of use
KR20130038841A (en) * 2010-03-19 2013-04-18 할로자임, 아이엔씨 Gas-pressured medication delivery device
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US11419632B2 (en) * 2010-04-23 2022-08-23 Mark D. Wieczorek, P.C. Transseptal access device and method of use
CN102958456B (en) 2010-04-29 2015-12-16 Dfine有限公司 Be used for the treatment of the system of vertebral fracture
FR2964851B1 (en) * 2010-09-21 2014-05-09 Neolix ENHANCED ENDODONTIC INSTRUMENT USING SLOT ALONG A CUTTING PORTION FOR PASSING A FLUID
GB2486652A (en) * 2010-12-21 2012-06-27 Peak Medical Ltd Infusion catheter with a detachable needle
US20120245528A1 (en) * 2011-03-22 2012-09-27 Navilyst Medical, Inc. Catheter with porous cuff
US8366685B2 (en) 2011-04-26 2013-02-05 Creative Vascular, Llc Systems and methods for phlebotomy through a peripheral IV catheter
US9186100B2 (en) 2011-04-26 2015-11-17 Velano Vascular, Inc. Systems and methods for phlebotomy through a peripheral IV catheter
US10076272B2 (en) 2011-04-26 2018-09-18 Velano Vascular, Inc. Systems and methods for phlebotomy through a peripheral IV catheter
US9089438B2 (en) 2011-06-28 2015-07-28 Spinal Elements, Inc. Apparatus for promoting movement of nutrients to intervertebral space and method of use
US9056182B2 (en) 2011-08-23 2015-06-16 Becton, Dickinson And Company Catheter having a pressure activated splittable feature
US9402975B2 (en) 2011-08-31 2016-08-02 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip
LT2750501T (en) 2011-08-31 2018-09-10 Organic Medical Ventures, L.L.C. Transdermal venous access locking solutions
US8855783B2 (en) 2011-09-09 2014-10-07 Enopace Biomedical Ltd. Detector-based arterial stimulation
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US20130345665A1 (en) * 2012-06-26 2013-12-26 Gary Swaddle Catheter system
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
CN104902836B (en) 2012-11-05 2017-08-08 毕达哥拉斯医疗有限公司 Controlled tissue melts
EP2740422A1 (en) 2012-12-05 2014-06-11 Custom Medical Applications Safety neural injection system and related methods
US10265504B2 (en) 2013-03-15 2019-04-23 Custom Medical Application Safety neural injection system and related methods
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US9610112B2 (en) * 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
EP3065673A4 (en) 2013-11-06 2017-07-12 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
JP2017507703A (en) * 2014-02-05 2017-03-23 バイオエヌテック アーゲーBioNTech AG Cannula, injection or infusion device, and method of using cannula or injection or infusion device
WO2015168391A1 (en) * 2014-05-02 2015-11-05 Cedars-Sinai Medical Center Injection catheter and catheter console platform
US10478249B2 (en) 2014-05-07 2019-11-19 Pythagoras Medical Ltd. Controlled tissue ablation techniques
WO2015171754A1 (en) * 2014-05-07 2015-11-12 Massachusetts Institute Of Technology Debridement apparatus using linear lorentz-force motors
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US20160346513A1 (en) * 2015-05-26 2016-12-01 Vanderbilt University Surgical device tip with arc length varying curvature
US10912922B2 (en) 2015-07-02 2021-02-09 Covellus Llc Modular medical device catheter system
US10814120B2 (en) 2015-07-02 2020-10-27 Covellus Llc Modular medical device catheter system
US10265482B2 (en) * 2015-10-01 2019-04-23 Soul Skins Llc Needle-point pen apparatus, methods, and systems for administering medication
US10300247B2 (en) 2016-02-03 2019-05-28 Velano Vascular, Inc. Devices and methods for fluid transfer through a placed peripheral intravenous catheter
CA3018985C (en) 2016-04-22 2021-11-16 Eli Lilly And Company Infusion site passivating device for extended wear during continuous subcutaneous insulin infusion (csii)
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
US9744344B1 (en) 2016-06-30 2017-08-29 Velano Vascular, Inc. Devices and methods for catheter placement within a vein
US10610668B2 (en) 2016-10-05 2020-04-07 Becton, Dickinson And Company Catheter with an asymmetric tip
JP2019534130A (en) 2016-10-27 2019-11-28 ディーファイン,インコーポレイティド Articulated osteotome with cement delivery channel
JP7256119B2 (en) 2016-11-28 2023-04-11 ディファイン インコーポレイテッド Tumor resection device and related method
US10470781B2 (en) 2016-12-09 2019-11-12 Dfine, Inc. Medical devices for treating hard tissues and related methods
US10660656B2 (en) 2017-01-06 2020-05-26 Dfine, Inc. Osteotome with a distal portion for simultaneous advancement and articulation
EP3600514B1 (en) 2017-03-21 2022-06-08 Velano Vascular, Inc. Systems and methods for controlling catheter device size
SG11201907120QA (en) 2017-03-21 2019-10-30 Velano Vascular Inc Devices and methods for fluid transfer through a placed peripheral intravenous catheter
CN107821996B (en) * 2017-12-05 2023-06-09 安徽至诚和信食品科技有限公司 Self-cleaning double-head injection needle for saline injection machine
US20220401261A1 (en) * 2017-12-07 2022-12-22 Harry Michael Lambert Ophthalmological surgery microsurgery instruments and methods of use in pars plana vitrectomy for increasing surgical precision and reducing vitreoretinal instrument insertions and removals and related trauma
US11510723B2 (en) 2018-11-08 2022-11-29 Dfine, Inc. Tumor ablation device and related systems and methods
US11554197B2 (en) * 2018-11-20 2023-01-17 BioMark, LLC Device with an open cell element
CA3138522A1 (en) 2019-04-30 2020-11-05 Boston Scientific Scimed, Inc. Endoscopic patch applicator
EP4017571A4 (en) 2019-08-20 2023-11-29 Velano Vascular, Inc. Fluid transfer devices with extended length catheters and methods of using the same
WO2021192283A1 (en) * 2020-03-27 2021-09-30 日本ライフライン株式会社 Drug solution injection needle and drug solution injection needle system
JP7373056B2 (en) 2020-03-27 2023-11-01 日本ライフライン株式会社 Chemical injection needles and chemical injection needle systems
CN111420169A (en) * 2020-04-09 2020-07-17 广州医科大学附属肿瘤医院 Side hole needle head
CN111420175B (en) * 2020-05-15 2021-11-02 咸宁市中心医院 Medical infusion bottle plug
CN111420176B (en) * 2020-05-15 2022-07-05 梁徐涛 Medical transfusion anti-drop plug
CA3197752A1 (en) 2020-11-26 2022-06-02 Avia Vascular, Llc Blood collection devices, systems, and methods
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator
US20230218309A1 (en) * 2022-01-11 2023-07-13 Covellus Llc Adapter for an electrical modular catheter system
WO2024047081A1 (en) 2022-09-02 2024-03-07 Universiteit Gent Catheter for delivery of therapeutic liquid formulation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5913856A (en) 1997-05-19 1999-06-22 Irvine Biomedical, Inc. Catheter system having a porous shaft and fluid irrigation capabilities

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE374641C (en) 1923-04-27 Ernst Kallmeyer catheter
US1124851A (en) 1913-03-26 1915-01-12 Edward E Burkle Process for curing meats.
US1192596A (en) 1915-09-16 1916-07-25 Benjamin K Albrecht Apparatus for injecting brine into meat.
US1370788A (en) 1919-07-21 1921-03-08 Good Frank Hoyze Meat-curing injector
US2112629A (en) 1936-09-29 1938-03-29 Lloyd Russel Trocar
US3076457A (en) 1961-02-14 1963-02-05 Copen Simon Irving Hypodermic needle
US4186745A (en) 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4173981A (en) * 1977-05-23 1979-11-13 University Of Utah Cannula for arterial and venous bypass cannulation
US4256102A (en) * 1979-05-14 1981-03-17 Monaco Anthony P Subcutaneous dialysis system
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
US4512768A (en) * 1982-09-10 1985-04-23 Avvari Rangaswamy Analgesic syringe
SE442377B (en) * 1984-06-29 1985-12-23 Mediplast Ab CATS, HEALTH OR SIMILAR DEVICE
US4838877A (en) 1985-08-06 1989-06-13 Massau Bruce A Polymeric hypodermic device
JPH02142576A (en) * 1988-11-25 1990-05-31 Japan Gore Tex Inc Catheter
US5021044A (en) * 1989-01-30 1991-06-04 Advanced Cardiovascular Systems, Inc. Catheter for even distribution of therapeutic fluids
US4968306A (en) * 1989-07-07 1990-11-06 Advanced Cardiovascular Systems, Inc. Intravascular catheter having an adjustable length infusion section to delivery therapeutic fluid
DE3943412A1 (en) * 1989-12-30 1991-07-11 Braun Melsungen Ag TRANSCUTANE IMPLANT CATHETER
US5069673A (en) * 1990-02-07 1991-12-03 Cordis Corporation Catheter with double step-down bore
US5085635A (en) 1990-05-18 1992-02-04 Cragg Andrew H Valved-tip angiographic catheter
EP0536296A4 (en) * 1990-06-26 1993-08-04 Cardiovascular Therapeutic Technologies, Inc. Method and catheter for intravascular drug delivery
US6224608B1 (en) 1990-08-10 2001-05-01 United States Surgical Corporation Tissue holding device and method
US5147334A (en) * 1991-01-02 1992-09-15 Moss James P Catheter for cholangiography
US5254106A (en) 1992-04-17 1993-10-19 Feaster Fred T Hydrodissection needle
US5380307A (en) 1992-09-30 1995-01-10 Target Therapeutics, Inc. Catheter with atraumatic drug delivery tip
AU673703B2 (en) 1992-11-10 1996-11-21 Seikagaku Kogyo Kabushiki Kaisha Injector and use of the same
US5389074A (en) * 1993-10-27 1995-02-14 The Regents Of The University Of California Body insertion tube with anesthetic jacket
US5425723A (en) * 1993-12-30 1995-06-20 Boston Scientific Corporation Infusion catheter with uniform distribution of fluids
CA2198259C (en) 1994-09-02 2006-08-15 Graham David Barrett Grooved phaco-emulsification needle
US5713861A (en) * 1994-10-17 1998-02-03 Vanarthos; William Trauma urethral catheter and method of using same
US5569197A (en) * 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
DE69629326D1 (en) 1995-02-15 2003-09-11 Joseph Eldor Spinal needle with several holes
US6010495A (en) 1995-03-17 2000-01-04 Tilton, Jr.; Eugene B. Instrumentation for endoscopic surgical insertion and application of liquid, gel and like material
DE19512607A1 (en) 1995-04-04 1996-10-10 Johann Dr Med Rull Completely tragmentation-free cannulas
US5603703A (en) 1995-04-28 1997-02-18 Medtronic, Inc. Selectively aspirating stylet
US6007479A (en) * 1996-07-08 1999-12-28 H.D.S. Systems Ltd. Heart assist system and method
US6283951B1 (en) * 1996-10-11 2001-09-04 Transvascular, Inc. Systems and methods for delivering drugs to selected locations within the body
WO1997015341A1 (en) 1995-10-23 1997-05-01 Racz Gabor J Jr Stellate block needle
US5643228A (en) 1995-11-13 1997-07-01 Uresil Corporation Catheter
US5662619A (en) 1995-11-27 1997-09-02 Zarate; Alfredo R. Venous dialysis needle
US5800407A (en) 1995-12-21 1998-09-01 Eldor; Joseph Multiple hole epidural catheter
US5738649A (en) * 1996-04-16 1998-04-14 Cardeon Corporation Peripheral entry biventricular catheter system for providing access to the heart for cardiopulmonary surgery or for prolonged circulatory support of the heart
FR2747908B1 (en) * 1996-04-25 1998-12-04 Chout Philippe IRRIGATORY SUTURE
US6117125A (en) * 1996-05-02 2000-09-12 Cook Incorporated Method for predetermining uniform flow rate of a fluid from a tubular body and device therefrom
IE80772B1 (en) * 1996-06-10 1999-02-10 Elan Corp Plc Delivery needle
WO1997047342A2 (en) 1996-06-10 1997-12-18 Elan Corporation Plc. Needle for subcutaneous delivery of fluids
US5735831A (en) 1996-07-10 1998-04-07 Cordis Corporation Expandable flowrate catheter assembly and method of making same
US6063069A (en) * 1997-05-19 2000-05-16 Micro Therapeutics Inc. Method and apparatus for power lysis of a thrombus
JP2002512552A (en) * 1997-07-22 2002-04-23 イーメッド コーポレイション Delivery of drugs into heart tissue by iontophoresis.
US5957901A (en) 1997-10-14 1999-09-28 Merit Medical Systems, Inc. Catheter with improved spray pattern for pharmaco-mechanical thrombolysis therapy
AU3374799A (en) * 1998-03-31 1999-10-18 Cardiogenesis Corporation Delivery of an angiogenic substance
US5885252A (en) 1998-06-03 1999-03-23 Liu; Wen-Neng Automatic safety infusion catheter needle
US6162202A (en) 1998-10-26 2000-12-19 Sicurelli; Robert Flexible syringe needle
ES2253907T3 (en) * 1998-11-17 2006-06-01 Henri Mehier DEVICE INTENDED TO ENSURE THE RELEASE OF AN ACTIVE SUBSTANCE DIRECTLY IN THE BANK OF A CELL FABRIC, MEANS OF IMPLEMENTATION OF THE DEVICE AND DEVICES APPLIED TO THE INJECTION OF ACTIVE SUBSTANCE IN SUCH DEVICE.
FR2790965B3 (en) * 1999-03-19 2001-04-20 Henri Mehier DEVICE FOR DELIVERING VAPOR DIRECTLY WITHIN ALL OR PART OF A TARGET HUMAN OR ANIMAL DEVICE, SYSTEM FOR INJECTING VAPOR INTO THE DEVICE
US6210376B1 (en) 1999-04-08 2001-04-03 New York University Cannulated delivery pin
US6497698B1 (en) 1999-05-20 2002-12-24 Cardiac Assist, Inc. Method and apparatus for treating a patient
US6350253B1 (en) 1999-07-19 2002-02-26 I-Flow Corporation Catheter for uniform delivery of medication
US6241710B1 (en) 1999-12-20 2001-06-05 Tricardia Llc Hypodermic needle with weeping tip and method of use
US6464662B1 (en) 2000-07-26 2002-10-15 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
US7586913B2 (en) 2001-03-01 2009-09-08 Mitsubishi Denki Kabushiki Kaisha Mobile IP packet communication system

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5913856A (en) 1997-05-19 1999-06-22 Irvine Biomedical, Inc. Catheter system having a porous shaft and fluid irrigation capabilities

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033345B2 (en) 2002-05-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Deflectable microimplant delivery system
US8002739B2 (en) 2002-05-21 2011-08-23 Abbott Cardiovascular Systems Inc. Deflectable microimplant delivery system
US8500680B2 (en) 2002-06-28 2013-08-06 Abbott Cardiovascular Systems Inc. Device and method for combining a treatment agent and a gel
JP2010285440A (en) * 2002-08-06 2010-12-24 Mytogen Inc Treating complex
JP2005534430A (en) * 2002-08-06 2005-11-17 ジェンベック, インコーポレイテッド Improved injection system
EP1743674A2 (en) * 2002-09-18 2007-01-17 Cardiac Pacemakers, Inc. Device to stimulate therapeutic angiogenesis for ischemia and heart failure
EP1743674A3 (en) * 2002-09-18 2012-05-09 Cardiac Pacemakers, Inc. Device to stimulate therapeutic angiogenesis for ischemia and heart failure
US7850644B2 (en) 2002-10-02 2010-12-14 Abbott Cardiovascular Systems Inc. Flexible polymer needle catheter
US6855124B1 (en) 2002-10-02 2005-02-15 Advanced Cardiovascular Systems, Inc. Flexible polymer needle catheter
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9687630B2 (en) 2005-04-19 2017-06-27 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US9775930B2 (en) 2006-11-17 2017-10-03 Abbott Cardiovascular Systems Inc. Composition for modifying myocardial infarction expansion
US8876792B2 (en) 2008-04-08 2014-11-04 Karolinska Institutet Innovations Ab Endoluminal medical access device
WO2010125166A1 (en) 2009-04-29 2010-11-04 Cardio3 Biosciences Injection catheter for delivering a therapeutic agent into a substrate

Also Published As

Publication number Publication date
US20010023349A1 (en) 2001-09-20
US7252654B2 (en) 2007-08-07
AU783463B2 (en) 2005-10-27
US20040220536A1 (en) 2004-11-04
US6855132B2 (en) 2005-02-15
US6547769B2 (en) 2003-04-15
US6241710B1 (en) 2001-06-05
JP2003517863A (en) 2003-06-03
DE60033688D1 (en) 2007-04-12
US20030130626A1 (en) 2003-07-10
EP1239776A2 (en) 2002-09-18
AU2275701A (en) 2001-07-03
ATE355018T1 (en) 2006-03-15
CA2394860A1 (en) 2001-06-28
DE60033688T2 (en) 2007-11-15
WO2001045548A3 (en) 2002-01-10
US6949087B2 (en) 2005-09-27
US20050288651A1 (en) 2005-12-29
EP1239776B1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
AU783463B2 (en) Hypodermic needle with weeping tip and method of use
EP0928135B1 (en) System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
JP5581692B2 (en) Microcatheter device and method for targeted drug delivery
US6796957B2 (en) Sterile aspiration/reinjection systems
US6595979B1 (en) Methods for sterile aspiration/reinjection of bodily fluid
US20020095124A1 (en) Lateral needle-less injection apparatus and method
AU2002318290A1 (en) Methods for sterile aspiration/reinjection of bodily fluid
AU2002320376A1 (en) Sterile aspiration/reinjection systems
CA2261022C (en) System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US20040236377A1 (en) System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
CA2547967A1 (en) System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000986533

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546291

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2394860

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 22757/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000986533

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 22757/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000986533

Country of ref document: EP